Folate status of plasma and  erythrocytes in health and disease by Omer, A.
THF FOLATE STATUS CF PI/!SNA AND
ERYTHROCYTES IN HEALTH AND DISEASE.
by
A. Omer, M.B. Ch.B. (Khartoum), M.R.C.P. (Edin.).
Thesis presented for the degree of Doctor of
Philosophy of the University of Edinburgh in
the Faculty of Medicine.
August, 1967*
Statement in terms of Ph.D.
Regulation 13 of the University
of Edinburgh.
Some of the results described in
Chapter II were presented as a
communication before the Scottish
Society for Experimental Medicine




INTRODUCTION TO THE THESIS 20
CHAPTER I s "Microbiologloal Method*".
Maintenance of Stock Cultures 21
Preparation of assay innoculae * 22
The lactobacillus casei assay method
for plasma and whole blood extracts 2A
The effect of autoclaved ascorbate phosphate
buffer on L. casei growth 29
The folate level of plasma compared to that
of serum 37
Hie effect of varying the length of autoclaving
time with pressure on the folate content of
whole blood 37
Folic acid clearance test * bo
Folic acid absorption test Al
Kfltlfflatloa of th. Titamin B12 ooat.nt of o.ru. ... «*
CHAPTER II l "The investigation of factors influencing
the release of assayable folate from erythrocytes".
Introduc tion A3
General procedures for investigating folate
release in whole blood haemolysates ............. AA
Preliminary experiments A6
Optimal (10050 folate release A9
Page.
Section I.
The effect of aacorbic acid on the folate











The effect of pH on folate release.
Preliminary experiment 65









The effect of modifying the pH on the folate





Plasma folate levels "all groups" 128













n- ■ i ■
GENERAL INTRODUCTION,
Page
Comparison between the effects of ascorbic
acid concentration, and pH on folate release . . '67
The effect of modifying the pH in the
absence of plasma on folate release from
erythrocytes . *.. 8?
Soction III.








The folate releasing properties of plasma














When reviewed in the light of modern knowledge, it
becomes obvious in retrospect, that Wills made the first
observation of folic acid deficiency in man.
Thus in (1931) she reported that a macrocytic anaemia
observed in Hindu women in Bombay and often but not necessar¬
ily associated with pregnancy responded either to "Marmite",
a concentrated extract of autolysed yeast or to a crude liver
extract.
Later studies by the same author (Wills and Bilimora
1932, Wills 1933* J93^» Wills and Stewart 1935) showed that
a similar megaloblastic anaemia could be produced in monkeys
fed on a diet similar to that consumed by the affected Indian
natives, and that the anaemia was also curable by yeast and
liver extracts.
A few years later it was shown that Anahaemin, a
more refined anti-pernicious anaemia liver extract, was
without effect on nutritional anaemia either in man or the
monkey and that it differed in this respect from Marmite or
crude liver extract (Wills, Clutterbuck and Evans 1937 (a)
and (b), Wills and Evans 1938). This was an observation
of great importance and interest since it Bhowed that Wills
factor and the extrinsic factor (Castle 1926) were not
identical.
It has been shown since that the folic acid content
of Marmite is about 60ug/g. (Welch and Heinle 1951, Kodicik
and/
2.
and Carpenter 19**8) which means that Wills was giving her
patients from 0.5 - lmg. of folic acid daily, an amount
well in excess of the dose necessary for a therapeutic
response in folic acid deficiency (Hansen and Weinfield 1962).
Microbiological assays of crude liver extracts gave a folic
acid content ranging between 0.7 - *f.5ug/ml» (Girdwood 195*0*
The presence of "fblic acid substances" in Marmite and crude
liver extract, and a report appearing later from India
describing the remission of macrocytic anaemia of pregnancy
following treatment with synthetic pteroylglutamate acid
under conditions relating to earlier observations (Benjamin
19*f6) lend strong support to the concept that Wills factor
was folic acid.
ISOLATION. SYNTHESIS AHD NOMENCLATURE
OF PTEROYLGLUTAMIC ACID AND RELATED COMPOUNDS.
Bacterial requirements for "folic acid":-
Hapid progress in the characterisation of "folic
acid substances" came with the use in assays of micro¬
organisms unable to synthesise folic acid for their own
needs. Snell and Patterson (19**0) pioneered the field by
showing that Lactobacillus casei required a growth factor
present in liver and yeast, which could be adsorbed and
eluted from charcoal. It was referred to as the norite
eluate factor and the liver Lactobacillus easel factor
(Stockstad 19*+3). The term folic acid (Latin folium = a
leaf) was introduced by Mitchell et al. (19*tl) to denote a
material/
material extracted from spinach and the green leaves of
many plants which was also present in yeast, kidney and
liver and which supported the growth of Streptococcus
lactis R.
Yet another name, vitamin Be, was given to a factor
in liver extract potent against deficiency anaemia in chicks
(Hogan et al. 1940) and isolated later in a crystalline form
and shown to support the growth of Lactobacillus casei
(Pfiffner et al. 1943). In 1943 Keresztesy and co-workers
reported the isolation of a factor active for S. lactis R.
"now known as S. faecalis". but relatively inactive for
Lactobacillus casei.
The issue was complicated further by the discovery
that yeast concentrates had a potent curative effect in anaemic
chicks but little microbiological activity for either L. casei
or S. faecalis unless previously treated enzymatically
(Binkley et al. 1944, Pfiffner et al. 1945, Mims et al. 1944).
The terms Be conjugate and Be conjugase were used to denote
these substrate and enzyme systems respectively (Bird et al.
1945).
Kames that were now being used included the norite
eluate factor, L. casei factor, folic acid, S.L.R. factor,
vitamin Be, vitamin M. (Day et al. 1938)» vitamin BIO and
Bll (Briggs et al. 1943) and vitamin Be conjugate.
The possibility that these factors were the same
substance was suggested (Mallroy et al. 1944, Briggs et al.
1945) and it was subsequently found that they could be replaced
in bacterial nutrition by pteroylglutamic acid or related
sifbs'tanc es/
substances.
The chemical structure and synthesis of the L. easel
liver factor was announced by Angler and co-workers in two
successive publications in 1945-46 (Angier et al. 1945 and
1946). Thev showed its molecular configuration to be a
pteridine grouping linked through p-aninobenzoic acid to a
single glutamic acid residue end suggested the name "pteroyl-
glutamic acid". Soon the chemical characterisation of more
related compounds followed in quick succession. These
included
1. Pteroyltriglutamic acid (Angier et al. 1946, I.ampen and
Jones 1946) (L. casei fermentation factor) a three
glutamic acid radicle conjugate active for h. caeei
but has no activity for 6. faecalis R.
Pteroylheptaglutamic acid (pteroylhexa-glutamyl glutamic
acid (Pfiffner 1946) Vitamin He conjugate) was isolated
from yeaat. It has no activity for either L. casei or
S. faecalis R. However an enzyme present in many animal
tissues will libera te assay able monoglutarnatea from it
(Juke and Stocks tad 194-8).
3. Pteroic acid. This was syntheeised by omitting the
glutamic acid grouping from PGA molecule; it is exclusively
active for S, faecalie R.
4. Rhizopterin (10 forraylpteroic acid, S.L.R. factor) was
isolated from the fermentation of Rhizopus nigricans
and is active for S. faecalis R.and inactive for both
L. casei and animals.
5./
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5. Follnic acid (Citrovorum Factor) (CF).
In (19^8) Sauberllch and Baumann made the observation
that unless a liver "Factor" was added, Leuconostoc citro-
vorura (pediococcus cerevisiae) failed to grow on a synthetic
medium. The synthesis of a substance with similar properties
and able to reverse the toxicity of ^ amino-pteroylglutamic
acid in mice, was announced in (1950) by Brockman and co¬
workers. In the same year Nichol et al. demonstrated the
ability of liver slices in vitro to convert PGA to citrovorum
factor (Nichol and Welch 1950). They showed that the reaction
was augmented by ascorbic acid and gluco-ascorbic acid. Later
work suggested that citrovorum factor, a relatively stable
compound, is a non-enzymatic degradation product of a highly
labile raetabolically active folate compound (Nichol et al. 1955)*
THE DEVELOPMENT OF MICROBIOLOGICAL
TECHNIQUES FOK FOLIC ACID ESTIMATION.
1. The Assay Mediat-
Most microbiological procedures for folic acid assay
are based on the method described by Teply and Elvehjem
(19^5) for S. faecalis and L. casei. These workers used a
titemetric method, for L. casei. utilising acid hydrolysed
casein in the basal medium and requiring a 30-72 hr.
incubation period. Robert and Snell (19k6) substituted
enzymatically digested casein for the acid hydrolysate
and were able to reduce the incubation period to 16 hours.
This/
This was followed by various inor modifications until the
question was to a large extent settled by the recent advent
of satisfactory commercial media for carrying out assay with
the three micro-organisms.
2• The extraction of folates from biological material:-
The demonstration by Toennies et al. (1955) that
folate activity in biological material is destroyed by heat
but is fully preserved when autoclaved in the presence of
ascorbic acid (Toennies and Usdin 1956) marked a major
advance in the area of microbiological folic acid estimation,
a procedure which involves autoclaving at least once. It
has provided investigators with a simple method for obtaining
protean free folate extracts from biological fluids and
tissues. Since then ascorbic acid concentrations varying
from .05 to 0.3g«% in phosphate buffer have been used by
various workers to prepare serum or blood extracts (Luhby
and Coopermann 19&5)•
3. The folate content of serur and whole blood as diagnostic
aids
Attempts by earlier workers to measure the basal folate
content of human serum or blood were uniformly unsuccessful in
demonstrating a significant difference that would distinguish
normality from deficiency. This is understandable in part
since most workers used S« faecalis (Schweigert et al 19^7i
hieweg et al. 195^» Chanarin et al. 1957 and 1958a,Cox et
al. I960), a micro-organism shown later not to respond to the
major component of serum or blood folates. Inadequate
protec tion/
protection of labile folate must have been the major cause
of low levels obtained in L. casei assays (Gchweigert et al.
19^8, Sir peon et al. 19^9, Spray 1952 (a) and (b)X These
results led some workers (Chanarin 1958, Luhby 1959) to
doubt the validity of folate estimations as diagnostic tools.
Indeed some doubted the existence of assayable folates in
the plasma at all (Chanarin 1958).
However, in 1959 Baker et al. published a 1. casei
assay method, by which they found that folate deficient
patients had significantly lower serum levels than normal
subjects or patients with uncomplicated Vitamin deficiency.
Baker's method paved the way for further studies in the
microbiological activity of human serum. Thus Herbert
(1961) found that 150mg.% ascorbic acid in the phosohate
buffer afforded a better protection for the labile folates,
and that the folate content of plasma is the same as that of
serum. Waters and Mollin (1961) 6howed a clear cut
difference between folate levels in deficient and normal
subjects and demonstrated the protective effect of ascorbic
acid on stored serum.
Provided the assay is done under standard conditions,
it has since beer possible to obtain reasonably reproducible
results. Causes of unsatisfactory results in micro¬
biological assays are adequately tabulated by Girdwood (1963)*
However, results obtained in different laboratories
employing the L. casei assay vary widely. This is
illustrated/
8.
illustrated below where the normal ranges of serum folate




2.1 - 28.0 Spray (1964).
2.1 - 9.5 Temperly et al. (1966).
2.3 - 18.6 Deller et al. (1966).
2.7 - 18.3 Davies and Kelly (1962).
3.4 - 11.6 Ball and Giles (1964).
*►.6 - 18.4 Kershaw and Girdwood (1964).
5.9 - 21.0 Waters and Mollin (1961).
7.0 - 15.9 Herbert (1966).
The normal range of serum folate
in eight published series*
THE CHEMICAL SATUKE OF THE SERUM FOLATE COMPOUHP(S).
Herbert's observation that human serum contains
folate activity* that supports the growth of L. casei but
not 3* faecalls or L* citrovorura, led him to believe that
the serum folate material must be pteroyl-triglutaraate
(Herbert 1961); a conclusion supported by previous
observations on the growth response of the three micro¬
organisms/
organisms to this folate compound (Usdin 19^9, Stockstad
195^» Rabinowitz i960). However, Larrabee et al. (1961
(a) and (b).) isolated a monoglutamate (N -methyltetrahydro-
folic acid) as an intermediate product of methionine bio¬
synthesis and Keresztesy et al. (1961) and Donaldson et al.
(1961) isolated a compound with similar properties from
horse liver. Both compounds produced the same effect on
the growth of the three micro-organisms as the serum folate
derivative. Working on these lines, Herbert and co-workers
by applying chromatography and conjugase treatment to serum
5
was able to prove that the serum folate compound is N -methyl
tetrahydrofolic acid monoglutamate (Herbert et al. 1962a.).
THE FOLATE COMPOUNDS OF WHOLE BLOOD AND THEIR
RELEASING FACTORS.
In 19^9 Simpson and Schweigert showed that incubation
at 37°C. and within a pH optimum of 6-8 markedly increased
the folate content of blood haemolysates obtained from
different species including man. They attributed this
effect to the presence in blood of "conjugases" which they
defined as "enzymes that liberate microbiologically
available folic acid from more complex forms of the vitamin".
They also demonstrated the effectiveness of "blood conjugases
in releasing folic acid from pteroylheptaglutamate. The
folate released, either from whole blood alone or from whole
blood with added pteroylheptaglutaraate, gave considerably
higher values when assayed with L. easel than when measured
with/
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with S. faecalis R. They condemned the use of
takadiastase ae an exogenous conjugase because they pointed
out that "blood conjugases" are capable of releasing variable
amounts of folic acid from conjugates in this substance.
In e&953 Toennies, Frank and Gallant, using dialysis
rather than heat to separate the folic acid released in blood
haemolysates, found that dialysates obtained at low
temperatures and against .05 M phosphate or acetate buffer
of pH 5*7 - 6.0 gave L. casei levels which were 20 to 100
times greater than previously reported values.
Later the same group of workers showed that washed
red blood cells and plasma when assayed separately under
conditions which yield high folic acid activity for whole
blood, are nearly inactive (Toennies et al. 1956). From
this they formulated the concept that the released folic acid
in blood haemolysates is the result of interaction of an
inactive red blood cell folate precursor and an enzymatic
plasma factor(s). In support of their postulated substrate-
enzyme system they pointed out that:-
(a) It is the red blood cell content of the folate precursor
rather than the plasma factor that determines the folate yield,
and that under certain conditions the precursor gives rise to
small amounts of assayable folates without the action of plasma.
(b) In accord with its protein nature, the plasma factor is
damageable by heat and is present in the highly purified plasma
protein Cohn fractions IV and V.
A./
11.
A. THE ERYTHROCYTE FOLATE PRECURSOR SUBSTANCE (FPS).
1. General Properties:"
In 19.6^ Iw&i et al. speculated on the possible
protein nature of the erythrocyte folate precursor substance
(FPS) and the similarity of its molecular size to haemoglobin
on the basis ofs-
(a) When haemolysates, prepared from washed erythrocytes,
were applied to a Sephadex column, FPS and haemoglobin
moved through the column at the same rate indicating that
they were of similar molecular size.
(b) 100% precipitation of FPS occurred at 80% saturation
of haeraolysates with ammonium sulphate. Further, when
haemolysates were dialysed, all the potential folate activity
remained in the impermeable matter. Both of these findings
lend support to the proposed protein nature of FPS. Further¬
more, when a solution of a crude lyophylised preparation of
FPS was applied to a DEAE column and the effluent analysed
for its protein and folate content, the fractions were found
to have a protein bound folate content of approximately 1%.
The predominant L. casei activity in these fractions
5
suggested to the workers the possible presence of N -
methyltetrahydrofolic acid, an observation to be confirmed
later (Noronha and Aboobaker 1963).
2. Chemical Nature
Usdin and co-workers (1956) analysed a concentrated
preparation of the erythrocyte folate precursors by paper
chromatographic and tetrazolium bioautographic techniques.
A/
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A complex situation was found in which none of the isolated
predominantly L. casei active fraction was identical with
any of the chemically well defined folate compounds at the
time, namely PGA, C.F. and pteroyltriglutamic acid.
Later Usdin (1959) subjected the folate material
to triethylamine ethyl cellulose column chromatography.
Nine peaks of folate activity were obtained, all of which
were identified by him as formylated folate compounds of
various structure. This led him to consider the folate
precursor as forraylated polyglutamyl derivatives.
However, Koronha and Aboobaker (1963) by extracting
blood folates under a rigorously controlled reducing
environment, presented evidence that the erythrocyte folate
5
precursors are conjugated forms of N -methyltetrahydrofolic
5
acid which on enzymatic degradation yield N -methyltetra-
hydrofolic acid raonoglutamates. This conclusion was based
on the almost exclusive activity of these extracts to L. casei
(a known characteristic of the N methyl derivatives of folic
acid), and the similarity of their behaviour on DEAE-cellulose
columns to the pattern shown to be characteristic of the
synthetic counterparts (Silverman et al. 1961, Wittenberg
et al. 1962). Usdin's finding of formylated compounds was
attributed by the same workers to his failure to maintain
a reducing atmosphere during extraction, a hazard that may
cause oxidative alteration of the C-l moiety (methyl to
formyl).
5
The presence of N -methylmonoglutamate in serum
(Herbert/
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(Herbert et al. 1962a) and the polyglutamate forms in the
red blood cells (lloronha et al. 1963) as well as the recent
demonstration of this folate derivative in human liver
(Chanarin et al. 1966) makes it the main circulating and
storage folate form in the human body.
£. THE FOLATE RELEASING FACTORS.
1. Exogenous Enzymes:
(a) The chicken pancreas conjugase.
Laskowski, Mims and Day (19^5) described the
presence of an enzyme in chicken pancreas that can release
3, faecalis active folates from their inactive precursors
in yeast. The enzyme was shown later to act optimally in
the presence of calcium ions, at a pH of 7*8 and a
temperature of 32°C. (Mims et al. 1945). Based on the
observation of Pfiffner and co-workers (1946) that the
enzyme must be a carboxy-peptidase, Mims et al. (1948)
classified it as "^-glutamic acid carboxy-peptidase by
showing its specificity for hydrolysing terminal glutamic
acid which has both of its carboxyl groups free and which
is linked through its amino groups to the y-carboxyl group
of the preceding glutamic acid.
(b) Hog kidney conjugase.
This is another folate releasing enzyme differing
from the previous one by not being affected by calcium
ions and by having a pH optimum of 4.5 (Toennies et al. (1959).
Both conjugases have been used by a number of




2, The Plasma Factor:
Toennies et al. (1959) investigated some of the
properties of the plasma factor using ® crude preparation
of the latter obtained from Cohn fraction IV. Rapid lose
of enzyme activity occurred on standing in dilute aqueous
solution. The complete regeneration of activity by
reagents like hydrogen sulphide, reduced glutathione and
mercaptoethanol suggested the presence of easily oxidisible
thiol groups that are vital for enzyme action. When a
solution of the enzyme was fractionated on a DEAE column
there was a marked variation of enzyme activity in the
obtained fractions, a finding that may suggest the presence
of more than one enzyme form in plasma.
To date one is not aware of any advance on Toennies*
original observations concerning this enzyme and its identity
remains obscure.
15.
CAUSCS CF FOLIC ACID DEFICIENCY lb HAH,
Conditions that raey be complicated with folic acid
deficiency are listed below. In the majority of these the
exact aetlological factors leading to the deficiency are well
recognised. In a snail group, however, these remain to be
established.
1. Kalabsorptive disease:
(a) Idiopathic steatorrhoea, (Frequently gluten
enteropathy.)
(b) Coellac disease. (Usually gluten enteropathy).
(c) Tropical Sprue.




k. Conditions associated with increased cellular turnover:
(a) Lympho-and myeloproliferative disorders.
(b) Haeraolytic anaemias.
(c) Sideroblastic anaemias.
(d) Leukaemias and reticuloses.
(e) Carcinomatosis.
5. Complicating the administration of certain drugs:
(a) Folic acid antagonists.






THE DIAGNOSIS OF FOLIC ACID DEFICIENCY.
1. Exclusion of deficiency
With the exception of a few rare conditions, the
finding of a normal serum vitamin in a patient presenting
with megaloblastic erythropoiesis is virtually diagnostic of
folic acid deficiency. The reverse is not true, however,
since megaoblastic anaemia may result from combined folate and
deficiency and also because some folate deficient subjects
may hav. "marrtnal" levels. Th. occurrence of each
cases makes the assessment of the folate status of patients
essential for reaching a confident diagnosis.
2. The Serum Folate;-
Despite the excessive variation in the serum folate
values reported from different units, there is general
agreement that megaloblastic folate deficient anaemias have
subnormal serum values, whereas in vitamin B deficient
anaemias there is a tendency for the active L. casei
material to accumulate and therefore for the serum folate
levels to be higher than controls. However, it is not
uncommon to encounter deficient subjects with marginal
or subnormal folate levels.
Herbert (1962) showed that the serum folate is the
first parameter to be effected during the development of
experimental nutritional folate deficiency in man. Thus
it dropped to abnormal levels three weeks after starting a
folate deficient diet, whereas macrovalocytosis, reduction
in the red blood cell folate content, a positive FIGLD and
the/
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the development of megaloblastic erythropoiesis took more
than three months to manifest itself. Reduction in the
serum folate level thus precedes the development of tissue
depletion by some time and may therefore be regarded as a
sensitive index of folate deficiency. This may account
for the occurrence of the occasional non-anaemic case in
which a low serum folate level is found in the absence of
any biochemical evidence of folate deficiency. Even so,
evaluation of such a situation can pose a difficult question
as to whether such a case is an early "subclinical" folate
deficiency or not. This will be discussed later in relation
to rheumatoid arthritis in which such a situation may be
encountered.
3. The red blood cell folate contentt-
Reported series have shown that the red blood cell
foXat. 1.T.1 may b. low in aith.r folat. or ^ d.fioi.noy
(Hansen and Weinfield 1962, Cooper and Lowenstein 196*t,
Hoffbrand et al. 19663). On its own such a parameter appears
to be useless in differentiating between the two deficiencies,
a point which will be evaluated later. Combined with the
serum folate and serum vitamin B12 estimations, it is claimed
to be a good index of the folate status of body tissues
(Hoffbrand et al. 1966a).
The Clearance Testi-
The value of the S. faecalis clearance test as an
index of the tissue folate saturation has been extensively
studied by many workers (Chanarin et al. 1958b, Metz et al.
1961/
18
1961, Hansen and Nystrom 1961, Grossowica et al. 1962). It
is well established that rapid clearance occurs not only in
folate deficiency but also in some vitamin deficient cases.
However, of more recent interest is the comparison between
the S. faecalis and L. easel clearances in vitamin and
folate deficiency. Herbert et al. (196a) and later Hogan
et al. (196*0 found a rapid S. faecalis clearance in both
deficiencies. The L. casei clearance, however, was also
rapid in folate deficiency but markedly delayed in vitamin
deficiency. This suggested to Herbert that vitamin
deficiency, the injected PGA (which is available for both
organisms) is rapidly converted, perhaps in the liver, to a
form which is only available for L. casei. The new folate
derivative "piles up" in the serum probably because vitamin B^
is required for its utilisation. The test is certainly of
academic interest in as far as the metabolic inter-relation-
ships of the two vitamins is concerned. However, one sees
no justification for its use as a diagnostic test for
differentiating the two deficiencies when simpler and equally
reliable tests are available.
5» Formiminoglutamic acid (FIGLU) excretion
Folate deficient patients excrete high amounts of
FIGLU in the urine, when given loading doses of histidine.
This has been used as a test of folate deficiency by many
investigators (Broquist 1956, Luhby 1957, Tabor and
Wyngarden 1958, Broquist et al, 1959, Knowles et al. I960,
Kohn/
19.
Kohn et al. 1961, Zalusky and Herbert 1962, Cbanarin and
Bennet 1962). r'TGLU excretion, however, ia not specific
for folate deficiency and a positive result may occur in
deficiency, liver disease and other conditions. As
pointed out by Kershaw and Girdwood (1964), a positive
result is only of value if interpreted with other diagnostic
parameters.
FIGLU can be determined electrophoretically, spectro-
photometrically, by microbiological methods or by paper
chromatography.
6. The Therapeutic Trial
The efficacy of this as a diagnostic test in folate
deficiency is adequately discussed by Luhby and Cooperman
(1965). They state that if done properly it is a very
sensitive and specific test of folate deficiency but that
certain conditions must be strictly observed, ftaaely:-
(1) The folic acid dose must not exceed .05 - 0.25»&.
daily, to avoid a non-specific response in vitamin
^12 conditioned by a "mass action".
(2) The patient must be put on a well controlled folate
deficient diet.
(?) For a significant response to occur, the reticulocyte
count must reach a peak between the 7th and 10th day
of the trial followed by a significant rise in the red
blood cell count and haemoglobin concentration.
It is obvious that such a test is only feasible in
units where controlled metabolic studies can be conducted.
20.
IlVi'HODUCTIOix TO THh. THESIS.
The present work is primarily concerned with the
investigation of factors that may influence the release of
easayable folate from erythrocytes and the evaluation of
the folate etatue of plasma and erythrocytes in health and
disease.
A description is given in Chapter I of the micro¬
biological techniques used in analysing the various samples.
The major part concerns the procedure employed for estimating
the folate eontent of plasma and whole blood extracts.
Chapter II embodies a series of experiments designed
to evaluate the effect of various factors on folate release
from erythrocytes. In addition the collection, storage and
preparation of whole blood samples prior to extraction is
described.
The folate status of patients with rheumatoid arthritis
is analysed in Chapter III and compared to that of normal
subjects as well as that of patients with megaloblastic





A. Deionised water was used throughout*
See Appendix A (I).
B. The cleaning of glassware used for folate and
vitamin estimation is described in Appendix A (II).
C. STOCK CULTURES.
Micro-organismsr-
1. Lactobacillus casei (NCI 8010).
2. Streptococcus faecalis (ATCC 8123).
3. Euglena gracilis Z strain (Algae and protozoa
collection, Cambridge).
a) Fluid Maintenance Media:
The preparation and storage of fluid maintenance
media for the three micro-organisms is described in
Appendix A (III).
h) Maintanenace of Stock Cultures;
i. L. casei.
ii. S. faecalis.
Both micro-organisms are maintained at 37°C. by
subculture on alternate days from fluid media to bacto-
raicroassay culture agar. An agar stab with a 2k hours
old culture of either micro-organisms was also stored at k°C»
and changed every week. Cultures have been maintained by
this method for long periods without evident mutation.
The procedure is shown below.
22 •
37°C. *°C.
Day I Fluid medium
1
Day II Agar stab (1)
Day III Fluid medium
J,








Subcultures of E. gracilis were made every k8
hours by adding k drops from a *f-5 days old culture to a
bottle of maintenance medium* These cultures were
maintained in a water bath (aquarium tank), the temperature
of which is kept at 28-30°C. by a circotherm heater* The
appropriate light intensity is provided by a double strip
fluorescent lighting system (40w) placed under the
transparent bottom of the tank*
c) PREPARATION OF ASSAY IKNOCULAEi-
1. L. easel and S* faecalis:-
The micro-organisms were sub-cultured from agar to
maintenance fluid media and grown at 37°C. for 2k hours*
The Lactobacillus casei culture was then transferred
aseptically into a sterile universal container and centrifu»ged
for hour at 3000g* The supernatant was decanted and the
growth/
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growth residue washed three times in physiological saline by
resuspension and centrigugation. Depending on the density
of the final suspension, 0.5 to 0,8 ml. of this was added with
a sterile one ml. pipette to a universal bottle containing
20 ml. of sterile physiological saline, to provide the
required innoculum. Using a sterile Pasteur pipette
(25 drops/ml.) one drop of the innoculum was delivered into
each of the assay tubes.
Centrifugation was found unnecessary for washing
S. faecalis. The liquid in the culture was decanted and the
cells at the bottom of the tube resuspended in physiological
saline. This was repeated three times and the ^th suspension
used for innoculating the assay tubes with a Pasteur pipette,
as described for L. casei.
2. E. Gracilis
A *t~5 days old culture was washed six times in
physiological saline by resuspension and centrifugation and
a drop of the 7th suspension delivered by a sterile Pasteur
pipette into each assay tube.
2k.
THE LACTOBACILLUS CASEI ASSAY OF THE FOLATE COWTEHT
OF PLASMA AND WHOLE BLOOD EXTRACTS.
The folate content of plasma and whole blood extracts
was measured by a slight modification of the method of Waters
and Mollin (1961).
The principles of the method are:-
1. Basal Medium
Difco folic acid casei medium was rehydrated by adding
9.4g./lOOml. of deionised water and boiling for 2-3 minutes.
2. The standard folic acid solutions
(a) The stock solution has a concentration of ki&g.% of
folic acid and is prepared by dissolving 20mg. of
crystalline pteroyl-glutamic acid (Lederle) in 500 ml.
of water. 1 or 2 pellets of sodium hydroxide were
usually added to help solution.
(b) The working solution always freshly prepared, has a
folic acid concentration of 1 mug/ml., achieved by
making a 1/40000 (1/200 x 1/200) dilution of the
stock solution in water. The dilutions were made
in volumetric flasks and each flask was always used
for the same folic acid concentration.
3. Preparations of samples for assay
(a) Plasma :
Heparinised plasma stored at -20°C. with lOmg. of dry
ascorbic acid/ml., was thawed at room temperature and diluted
1:20 (in a universal bottle) with 0.1 M phosphate buffer
containing/
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containing 200mg.% ascorbic acid* The lt20 plasma buffer
solution was autoclaved for 2-J minutes at 15 p.s.i.* cooled*
centrifuged and filtered. The protein-free extract was then
diluted with an equal volume of water and assayed on the same
day, two ml. being mixed with an equal volume of basal medium
giving a final plasma dilution of 1»80.
A duplicate extract was prepared from each sample and
assayed on a different day and the mean of at least two results
agreeing within X0°/> taken to represent the folate content of
the sample.
(b) Whole blood:
Whole blood haemolysates were prepared in different
ways e.g. by varying the pH, ascorbic acid concentration,
temperature etc. These methods are described in detail in
Chapter II.
For extraction, however, and unless specified,
haemolysates were mixed with 0.1 M phosphate ascorbate buffer
to give a final blood dilution of IslOO and a final ascorbic
acid concentration of 200mg.%. When haemolysates contained
differing amounts of ascorbic acid, the ascorbic acid content
of the buffer was adjusted accordingly to give the desired
200mg.% in the final mixture.
The samples were autoclaved for 5 minutes at 15 p.s.i.
to effect complete protein precipitation. The extracts ,
separated as for plasma, were stored at -20°C. until assayed
at a final dilution of 1/600 to 1/800. Samples were always
extracted/
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extracted and assayed independently at least twice, and the
average of two results that agreed within 10> taken as the
folate content of the blood sample.
20 ml. amounts of ascorbate phosphate buffer to be
added later to standard tubes were autoclaved with each batch
of plasma or whole blood samples.
The preparation of phosphate buffer is described in
Appendix A (IV).
4. Assay procedure:
The assay was carried out in 6 x -J" Pyrex test tubes.
Four tubes were used for each sample. Two ml. of the basal
medium were delivered with an automatic dispensor into each
tube. Using a five ml. pipette, two ml. of the diluted plasma
or whole blood extract were added to each of the four tubes
which were then covered with oxoid caps and placed in order in
wire racks.
A control "pooled normal" plasma was included in each
assay batch.
The standard tubesTable (1).
The standard row included nine tubes set up in
duplicate and containing 0 to 1.4 mug. of folic acid as well
as one uninnoculated blank containing NO folic acid.
Autoclaved ascorbate phosphate buffer was found to
stimulate L. casei growth and was therefore added to standard
tubes (0.6 ml/tube).
The standard was placed with the sample tubes in the
wire/
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wire racks and the whole assay sterilised for 10 minutes at
10 p.s.i. and allowed to cool to room temperature.
INNOCPLATION. INCUBATION AHD CALCULATION OF THE RESULTS:-
Plasma and whole blood extracts are usually
colourless. One tube selected at random from a sample
was therefore set aside as a blank for each dilution of
either extract. The remaining tubes were innoculated as
described.
The assay was incubated at 37°C. for 16-18 hours and
growth density measured with a Hilger Spekker using a green
filter (Kodak No. 3-^500).
Standard growth was plotted on arithmetic graph paper
against the amount of folic acid per tube.
The optical density (O.D.) of the blank was
subtracted from that of the sample tubes and the amount of
folic acid per tube read from the standard curve. The
average of each of the four tubes was then taken and
multiplied by the dilution factor to obtain the sample's
folate content in raug/ml.
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THE EFFECT OF AUTOCLAVES ASCORBATB PHOSPHATE
BUFFER ON L. CASEI GROWTH.
Herbert (1961) showed that L. casei growth was
stimulated by both ascorbic acid and phosphate buffer. Spray
(1964) and Temperly et al. (1966) obtained similar results by
adding ascorbic acid to the basal medium. Waters and Mollin
(1961) on the other hand found no effect on growth when auto-
claved ascorbate phosphate buffer was added to standard tubes.
The basal medium used in the present work contains no
ascorbic acid. If L. casei growth is enhanced by ascorbate
phosphate buffer, this must be added to standard tubes to
avoid the occurrence of erroneously high folate results due
to its presence in sample tubes. This was investigated as
follows:-
Five standards containing 0, 0.3, 0.45, 0.6 and 0.9 ml.
respectively of autoclaved ascorbate phosphate buffer per tube
were prepared on the same day. Each was set up as in Table 1
except that the folic acid content ranged from 0 to lraug. per
tube and,depending on the amount of buffer added, the quantities
of water were changed accordingly to give final volumes of
4 ml. per tube. The buffer quantities were selected to
cover those calculated to be present in the final assay
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0-4 0-6 0 6 1-0
Folic acid mug/tube
A- 0-6ml of autoclaved ascorbate phosphate buffer/tube.
B - No ascorbate phosphate buffer.
The offset of autoelared aocorbate phosphata







Final dilution of sample.
Plasma Blood




The calculated quantities of ascorbate phosphate
buffer per assay tube at various assay dilutions
of plasma or whole blood.
* Usual assay dilutions.
Results i-
1. Table (3) compares microbiological growth in the five
standards containing the different quantities of auto-
claved ascorbate phosphate buffer.
2. Two standard curves set up with and without autoclaved
ascorbate phosphate buffer are shown in Figure (1). The
folate results of 16 plasma samples assayed concurrently
with and read from both curves are shown in Table (4).
32.
TABLE (3).
S tandard A B C D E
Autoelaved ascorbate
phosphate buffer 0 0.3 0.45 0.6 0.9
al./tobe.
Folio acid mug/tube Optical density z 100
0.0 2 4 3 2 3
0.1 10 12 14 15 15
0.2 16 19 21 20 20
0.4 20 25 2? 27 28
0.6 26 31 33 35 34
0.8 31 35 38 39 40
1.0 36 40 44 45 45
Tha effact of autoclaved ascorbate phoaphata buffar
on tha growth of L.vcaaai in standard tubes.
N.B. Each standard was set up in duplicate. The
figures represent the average of the two readings
which showed very little difference.
35
TABLE CO.























Duplicate folate results of 16 plasma samples calculated
from the two standard curves shown in Fig, (1).
* Megaloblastic v itamin defici®n6 subjects.
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COMMENT s-
Table (3) and Figure (1) show that autoclaved
ascorbate phosphate buffer causes a marked stimulation of
micro-organismal growth. It can also be seen in Table (3)
that while 0.45 - 0.9 ml. of buffer per tube gave similar
responses, less growth occurred in the presence of 0.3 ml*
per tube. Autoclaved ascorbate phosphate buffer prepared
with each batch of samples during extraction was therefore
added to standard tubes throughout the present work. The
volume selected 0.6 ml. per tube (Table 1) was technically
convenient and had the same stimulant effect on bacterial
growth as the quantities calculated to be present in the
usually employed dilutions namely 0.45 to 0.9 ml. per tube.
The lower results obtained by this method
(Table 4) should represent a better approximation of the
folate content of samples than those calculated from standards
containing no ascorbate phosphate buffer.
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ACCURACY OF THE METHOD:
1. Reproducibility of results in duplicate assays:•»
(a) Plasmat
35 random samples were assayed twice on two consecutive
days. The range of difference between the duplicate
assays was 1 to 20% with a mean of 8% and SD jh 5*9%
(b) Whole bloodt
Duplicate assays were carried out in the same way on
4-7 whole blood samples. The difference ranged from
0 to 25% with a mean of 8,4% and SD £ 6.2%.
2• Recovery of added folic acid:-
Folic acid was added to five different plasma samples.
The recovery varied from 89 to 100% when 5nug. were
added to each and 85 to 97% when lCmug. were added.
3. Variation in the same a3say?-
(a) A plasma sample was assayed 15 times in one
assay. The coefficient of variation was 10%.
(b) A whole blood sample was treated in the same way.























































THE FOLATE OVSI OF PLAHMA C JMPAKED
TO THAI' OF SEBUM.
METHOD:
20 ml. of blood were obtained from each of 16 subjects.
10 ml. were added to a universal container and allowed to clot
for 2 hours at room temperature. The remaining 10 al. were
delivered Into a heparinised bottle ana plasma separated by
immediate centrifugation. Plasma and serum were stored at
-20°C. with 10mg. of ascorbic acid per ml. and the 32 samples
assayed later in one batch as described.
RESULTS:
The results of such an assay are shown in Table 5.
These indicate as previously reported by Herbert (1961) that
the folate levels of plasma and serum obtained from the same
subject at the same time are similar. As a 20 ml. heparinised
blood sample was sufficient for estimating both plasma and whole
blood folate contents and as all subjects studied in the present
work had both estimations done, plasma was preferred to serum for
folate estimation.
THE EFFECT OF VARYING THE L-SHGTH OP aUTUCLAVIhO
WITH PRESSURE ON THE FOLATE CQKTBHT OF'WHOLE BLOOD.
Qrosaowicz et al. (196.2) extracted whole blood folate
by axitoclaving for 20 minutes at 15 p.s.i. Hoffbrand et al.
(19664 on the other hand, recommended 2-J minutes at 10 p.s.i.
but found that protein precipitation was not always complete.
The effect of varying the length and pressure of autoclaving on
whole blood folate was therefore determined in order to select




























Theeff ctoftdurationandpressurefau o lavingo wholeblo dfolat .
39.
without affecting folate stability.
METHOD:
Each of three blood specimens was haeraolysed at a dilution
of 1:10 by adding 1-J ml. of blood to 13-J ml. of a freshly prepared
lg.%ascorbic acid solution. After ten minutes at room temperature,
the three haemolysates were stored at -20°C. for one hour and then
thawed at room temperature. Two ml. of each haemolysate were
then added to each of five universal bottles containing 18 ml. of
0.1 M phosphate buffer with 100mg.% assorbic acid. The final
blood dilution in all samples was 1/100 and the final ascorbic
acid concentration 200mg.%.
Triplicate bottles (representing the three blood specimens)
were then autoclaved for periods ranging from 2-J minutes at 10 p.s.i.
to 13 minutes at 15 p.s.i. and the folate content of the extracts
determined as described.
RESULTS s
Similar folate values were obtained in eqch of the three
blood specimens when subjected to the different autoclaving
conditions (Table 6). This indicates that under these
circumstances, folate yield was not affected by either the duration
or pressure of autoclaving.
All extracts obtained by heating for 2-J minutes at 10 p.s.i.
and some of these prepared at 10 p.s.i. for 5 minutes or 15 p.s.i.
for 2-J minutes had a yellowish tinge indicating incomplete protein
precipitation. The remaining extracts were colourless.
Autoclaving for 5 minutes at 15 p.s.i. was therefore




The clearance of injected folic acid was performed
by the method of Chanarin et al. (19581). A solution of
folic acid in physiological saline (lmg./ml.) was given
intravenously, the dose being 15 ug./kg. of body weight.
10 ml. of blood were obtained by venepuncture at 3, 15 and
30 minutes respectively after the intravenous dose and
allowed to clot at room temperature; the serum was then
separated aseptically and stored at -20°C. until assayed,
using S. faecalis as the test organism.
For assay, 4 dilutions in water were prepared
aseptically from each sample and 2 ml. of each dilution
added to a tube containing 2 ml. of DIFCO folic acid assay
medium previously sterilised by autoclaving for 10 minutes
at 10 p.s.i. The final assay dilutions were as follows
1. 1/250, 1/175, 1/125 and 1/100 respectively for the 3
minutes sample.
2. 1/100, 1/75» 1/50 and 1/^0 for both the 15 and 30 minutes
samples.
A standard row containing 0 - *tmug» of folic acid per
tube was included and the assay innoculated as described.
Microbiological growth was measured after a 16 - 18
hours incubation period at 37°C. and the results calculated
as described for the L. casei method.
A second assay was always performed and the dilutions
c hanged/
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changed if necessary. The test gave the following values in
normal controls
175 - 95mug. of folic acid/ml. of serum at 3 minutes.
70 - ■to " " " 15 minutes.
50 - 23 " " " 30 minutes.
rcuc ACie ABSORFTIOK.
The test used for folic acid absorption was that described
by Girdwood (19,33* i960). The patient was given 5»g« folic acid
(Lederle) subcutaneously and the urine collected in a brown bottle
toluene for 2V hours (Specimen A.). A 5mg. dose was then given
orally and a second 2k hour urine collection made (Specimen B.).
The folic acid in the urine was measured with S. faecalis.
Samples were diluted with water and 5 ml. added to each of three
tubes containing 5 ml. of Difeo folic acid assay medium. A
standard containing 0-10mug. of folic acid per tube and final
volumes of 10 ml. per tube was included. The assay was
sterilised by autoclaving for 10 minutes at 10 p.s.l. Innocul-
ation, incubation end calculation of results were as described
for the clearance test.
The folic acid excretion index:
Output of .folic acid in the urine after 5&g. orally. .QQ
Output of folic acid in the urine after 5*g» subcut. x
was calculated.
A folic acid output of less than 1.5«g/24 hours after
the oral dose and an excretion index of less than 75% indicated
malabsorption.
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THE VITAMIN B,^ CONTENT OF SEBUM.
1 ■' 1 '12 1 "
The preparation of samples for assay, the final
assay volume and the setting of the standard tubes were
exactly as described by Anderson (1964). The basal medium
was different, however. DIFCO Euglena assay medium
was used rather than the basal medium recommended by Hunter
et al. (1956). The assay was innoculated and incubated
for 4-5 days as described. Growth was measured by a
Hilger Spekker using a red filter (Kodak No. 8*}4680).
The range of the serum Vitamin concentration
in normal controls is 150 - 1000 Umg./ml. Megaloblastic
vitamin B^" deficient subjects always have values less than
lOGmug./ml. and in 26 cases investigated in the present
study the levels ranged from 0 - 88uug./ml.
CHAPTER II.
THE INVESTIGATION OF FACTORS INFLUENCING THE
RELEASE OF ASSAYABLE FOLATE FROM ERYTHROCYTES»
^3.
INTRODUCTION.
Toennies and co-workers (1956) showed that a factor
present in plasma is important for the release of assayable
folate from inactive precursors in erythrocytes and that this
o
release is enhanced by the incubation of whole blood at 37 C.
in phosphate buffer (pH 6 - 6.1), prior to precipitation of
the proteins by autoclaving.
These conditions for "maximal" folate release i.e.
incubation at 37°C. and pH 6 - 6.1 have since been adopted by
most workers who have estimated the folate content of whole
blood (Grossowicz et al. 1962, Hansen and Weinfield 1962,
Cooper and Lowenstein 196^, Grzesinkowicz et al. 1966).
Since the commencement of the present work, however,
Hoffbrand et al. (1966ej) have found that incubation does not
increase the folate content of haemolysates prepared in lg.$
ascorbic solution. This finding of "maximal" folate release
at room temperature and pH 3.6 - 3.8 is at variance with the
original observations of Toennies et al. (1953) who found that
folate yield fell almost to zero at pH k and was maximal within
a narrow pH range around 5.7. This led them in later work
(1956) to consider pH 6.0 as optimal for plasma factor action.
The prime object of this part of the Thesis was to
investigate factors which may influence folate release from
erythrocytes. This was achieved by studying the effects of
the/
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the following factors on the asaayable folate content of whole
blood haemolysatesj-
1* Ascorbic acid concentration*
2. pB.
Temperature, time and degree of haemolysis.
4. Relative concentration of erythrocytes to that of plasma.
5. The folate releasing ability of plasma from patients with
tfitamin or folate deficiency as compared to normal.
general procedures for investigating folate release in whole
blood haemolysates.
The following methods apply to the majority of
experiments to be described in this Chapter.
1* Collection of blood
Heparinised blood samples were used throughout.
40 ml. of blood were obtained by venepuncture from
healthy subjects with a normal peripheral blood picture and
20 ml. transferred into each of two sterile universal containers
(Vol. 25 ml.) containing 0.1 ml. of heparin (25,000 units/ml.).
The plasma was separated by immediate centrifugation for jr hour
at 1500g. 5-6 ml. of the plasma to be used for folate
estimation was stored at -20°C. after the addition of lOmg. of dry
ascorbic acid per ml. The remainder was recombined with enough
of the red cells to give a final packed cell volume of 30% + 2%.





Many of the experiments were conducted at room
temperature. Unless specified this means a temperature of
21 + 2°C. (daily temperature readings were taken during the
execution of these experiments).
3. pH determination;"
A Beckman model 72 pH meter was used to determine the
pH of all haemolysates. To avoid "carry over" from one sample
to another, pH determination was always done after aliquots
had already been removed for extraction.
k. Extraction (protein precipitation)
Haemolysates were always extracted in duplicate by
adding 2 ml. to each of two universal containers each contain¬
ing 18 ml. of 0,1 M phosphate buffer pH 6.0 - 6.1. The
ascorbic acid concentration in the blood buffer solution was
always kept constant at 200rag%. For haemolysates containing
little or no ascorbic acid (0 - 50mg%) a 200mg% ascorbate
phosphate buffer was used. When haemolysates contained 100 -
1000mg% ascorbic acid the buffer ascorbic acid content was
reduced accordingly to give the desired 200mg% in the final
mixture.




This is essentially a verification of the findings
of Hoffbrand et al. (196&), that maximal folate release can
be achieved without incubation, by the haemolysis of whole
blood in a solution containing lg.% ascorbic acid.
METHOD:
9 ml# volumes of a freshly prepared lg.% ascorbic
acid solution were dispensed into each of 9 pairs of sterile
universal containers.
To each of the pairs was then added a 1 ml. aliquot
of heparinised blood obtained from each of 9 normal subjects
thus giving a 1/10 dilution of each haemolysate.
One set of haemolysates was incubated at 37°C. for 90
minutes; the duplicates were frozen at -20°C. for one hour
and then thawed at room temperature.
The pH of all frozen samples and three of the incubated
ones was measured as described.
Haemolysates were extracted in duplicate with phosphate
buffer and assayed as in Chapter I. The folate values were
calculated as mug/ml. of packed cells (See Appendix B.H for
formula).
RESULTS:
The folate value obtained after freezing and thawing
was expressed in each case as a percentage of that obtained
after incubation at 37°C. (Table 7). The Table also shows
the/
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110 103 97 103 108 96 90 93 103 100.3% 7
fiaemolysate
pH.
3.6 3.6 3.7 3.6 3.7 3.6 3.6 3.6 3.7
1. Folate release after freezing and thawing
expressed as a percentage of that after incubation.
2. Haemolysate pH.
COMMENT:
The mean folate value of the frozen samples is 100.3% ♦
7% which is not significantly different from that of the
incubated standards. These results confirm those of Hoffbrand
et al. (1966) that incubation is not necessary for maximal
folate release providing that the blood is treated by the method
described. The pH values of the three frozen samples were
identical with those of their incubated duplicates.
All haemolyaates turned brown within three minutes of
the initial dilution and the pH values in Table 7 suggest that
this colour change may he due to the formation of acid haematin*
The/
T£e pH 3.6 - 3.7 of these baemolysatee Is of interest ae it
rears that the plasma factor is active at very low pH values.
Based on these results, a detailed study of the effect
of ascorbic acid on folate release was first made.
^9.
OPTIMAL OR 100% FOLATE RELEASE.
Folate release was frequently assessed and compared
in a single blood specimen under a variety of experimental
conditions. In order to facilitate analysis, the folate
results of each blood specimen were related as percentages
of its "arbitrary optimal or 100% folate release", defined as
the amount of folate (mug/ml. of packed cells) obtained when
a blood sample is haeraolysed at a dilution of 1/10 in lg.%
ascorbic acid solution and the haemolysate is incubated for
90 minutes at 37°C.
50.
SECTION I.
THE EFFECT OF ASCORBIC ACID ON THE
FOLATE CONTENT OF WHOLE BLOOD HAEMOLYSATBS.
This section consists of two experimental series
(A. and B.) designed to investigate the effect of differing
ascorbic acid concentrations on the release of aesayable
folate in whole blood h&emolysates.
The blood dilution was 1/5 in Series A. and 1/10 in
Series B. Complete haemolysis was ensured in all samples by
freezing and thawing. All samples were extracted and assayed
without incubation at 37°C.
EXPERIMENTAL SERIES A.
METHOD:
1* Nine blood specimens each with an approximate volume
of 30 ml. and a packed cell volume of 30% * 2% were used. No
more than two specimens were analysed each day.
2. Fresh ascorbic acid aqueous solutions of concentrations
0t 25, 50, 100, 250, 500, 750 and 1000mg.% respectively were
prepared.
3. Haemolysis was carried out in sterile universal
containers by combining 3 ml. volumes of a blood specimen with
12 ml. of each ascorbic acid solution. In this way 8 haemolyeates
with ascorbic acid concentrations of 0, 20, kOt 80, 200, *K)0,
600 and 800mg.% were prepared from each specimen. The final
blood/
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blood dilution in each ease was 1/5 and the final haemolycate
volume 15 ml.
4. After 10 minutes at room temperature all haeraolyeates
were stored at -20°C. and one hour later allowed to thaw at
room temperature. Complete thawiug usually took 40-50 minutes.
However all sample© were given one hour at room temperature.
5. The degree of haemolysis was always tested for after
thawing by removing 3 ml. volumes from haonolysates containing
0, 20, and 40a»g.% ascorbic acid, centrifuging for 5 minutes at
3000g. and estimating the haemoglobin content of the supernatant
after appropriate dilution. These values were then compared
to the haemoglobin content of the blood sample and complete
haemolysis assumed when the two values were found to be equal.
An "optimal" (1009c) folate release preparation was
mads from each blood specii-ien by incubating a 1/10 haemolysate
in lg.& ascorbic acid for 90 minute© at 37°C. (p« ^9 )•
The pH of all haemolys&tea was determined as described.
Haemolys&tes were extracted with phosphate buffer and assayed
as in Chapter I and the folate result© of each set of haemolysates
calculated as percentages of "optimal folate release" in the
parent blood specimen.
RESULTS:
Each horizontal set of values in Table 8 rsprsssnts
individual percentages of folate release in a single blood
specimen calculated as described and arranged under the
appropriate ascorbic acid concentrations. The folate
percentages/
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percentages are also grouped in eight columns under the
different ascorbic acid concentrations and the mean (SD+1)
calculated for each group. The significance of these results
is summarised in Table 9«
Haemolysate pH:-
The pH v/ae fairly constant within any group of
haemolysates prepared at a gi\^en ascorbic acid concentration.
The mean values (Table 8) ranged from 7.47 in the absence of
ascorbic acid to 4.25 in haeraolysates containing 800rag.%.
Series A. (Blood dilution 1/5)•
TABLE (8).
Group No. i 2 3 4 5 6 7 8
Haemolysate
ascorb. acid 0 20 40 80 200 400 600 800
concn. rag.%
Blood specimen Ft late r elease % of aptimua •
No.
1 4o 44 44 59 90 100 93 100
2 45 39 52 61 90 96 93 96
5 38 34 48 70 103 95 100 95
4 41 46 51 64 91 97 95 100
5 42 46 46 62 97 100 100 100
6 47 45 48 55 95 100 97 98
7 63 63 68 68 95 102 95 97
8 60 60 67 71 96 ! 91 100 100
9 48 49 51 58 99 97 98 98
Mean 47* 47 53 63 95 98 97 98




7.1+7 7.35 7.25 6.90 1 5.73 4.75 4.25
The relationship between haemolysate ascorbic acid








1 » 2 0 - Not sig.
2-3 1.1*28 Ml M
5 - k 2.9*0. P .01 Significant
k - 5 12.705 P .001 Highly aig.
5-8 1.550 Not cig.
6-8 0.8621 tt
7-8 0.7516 IIA P.'
Comparison between the mean percentage folate
yields of the various groups shown in Table 8.
COMMENT:
Tables 8 and 9 show thatt-
1, Raising the haemolysate ascorbic acid concentration fros
0 to *M)mg9f did not alter the folate content significantly.
2. The first significant rise in the mean percentage folate
yield occurred in the presence of SOrag# ascorbic acid (P<.01).
At 200ms# "maximal folate" values were obtained in Samples J
and 9f the mean percentage folate release in this group is




3. There is a progressive fall in pH with increasing
ascorbic acid concentration and the highest folate yields -
over 90% - occurred at pH values less than 6.0.
Factors which may be responsible for this pattern of folate yield;
(a) Haemolysis:
Haemolysis was complete when tested in the first three
groups. Inadequate haemolysis can therefore be excluded as a
cause of low folate yield at low ascorbic acid concentrations.
(b) Potentiation of the plasma factor by higher ascorbic acid
concentrationsi
It is possible that increased ascorbic acid concentrat¬
ions may directly affect the plasma factor with resultant
increased folate release. Toennies et al. (1963) concluded
that thiol groups were important for the plasma factor activity.
In their experiments, enzyme activity quickly dropped on
standing at room temperature in aqueous solution, but was
restored by hydrogen sulphide or reduced glutathione. In the
same way, these labile SH groups may well be protected by the
reducing action of ascorbic acid when present in higher
concentrations.
(c) A pH effect?
It is conceivable that the high folate release at
higher concentrations of ascorbic acid is due to its acidifying
action. The role of ascorbic acid here would be to reduce the
pH of the reaction to optimum values for the plasma factor.
This/
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This would suggest that the pH optimum of the plasma factor
Is in fact much lower than that usually accepted namely 6.0 -
6.1.
(d) Lability of the released folate?
Folate may have been released equally in all haemolysates
but ascorbic acid concentrations in excess of 80mg.% are necessary
to prevent oxidation.
(e) Maximal folate release was obtained in haemolysates
containing ascorbic acid concentrations of 200mg.% or more
without incubation. Possibly this does not apply to lower
ascorbic acid concentrations when a temperature of 37°C. may
be important.
(f) Haemolysates were combined with phosphate buffers
containing appropriate ascorbic acid concentrations to give a
final concentration of 200mg.% during autoclaving. Better
protection of folate during extraction or a greater stimulation
of bacterial growth by higher ascorbic acid concentrations
cannot therefore be a factor in producing higher folate values.
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EXPERIMENTAL SERIES B.
This differs in only one respect from Series A,
namely blood was haemolysed at a dilution of 1/10 instead
of 1/5. Blood specimens No. lt 2 and 3 in this series were
taken from the same subjects as No. 5« 6 and 7 respectively
in Series A.
METHOD:
10 blood specimens were haemolysed at a dilution of
1/10 by combining 1-J- ml. aliquots of each with 1>J ml.
quantities of freshly prepared ascorbic acid solutions
covering the following concentrations:- 0, 25» 50, 100, 250,
500, 750 and 1000mg.% respectively. Haemolysis was carried
out in sterile universal containers and the haemolysate
ascorbic acid concentrations were 0, 22.5, ^5, 90, 225, ^50,
675 and 900mg.% respectively.
k blood specimens were haemolysed over the whole range
of ascorbic acid concentrations thus obtaining 8 haemolysates
from each.
In 3 specimens the 50mg.$ ascorbic acid solution was
not used and therefore only 7 haemolysates were obtained from
each of them. Only 5 haemolysates were prepared from each
of the remaining three specimens.
Haemolysates were treated by freezing and thawing as
in Series A and their pH values determined as described.
An "optimal folate release" haemolysate was prepared
from/
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Series B. (Blood dilution 1/10).
TABLE (10).
Group No. 1 2 3
i




0 22.5 45 90 225 450 675 900
Blood specimen
No. % Folat i release.
1 42 61 69 96 93 93 100 100
2 41 62 70 90 94 94 100 95
3 68 76 81 95 100 102 98 100
4 34 60 68 96 100 100 100 100
5 46 58 90 91 92 92 92
6 26 48
-
mm 97 90 100 94 97
7 42 73 - 96 100 100 108 104
8 25 43
i
75 100 - - mm 103
9 42 67 82 100 — - 100
10 33 61 78 92 - - mm 92
Mean 40 61 75 95 95 97 99 98
SD ♦ 12 10 6 3.6 5.8 4.0 5.2 4.2
Mean haemolysate
pH
7.29 6.8? 6.63 5.83 4.48 4.13 3.9 3.67
Relationship between haemolysate ascorbic acid
concentration, mean pH and percentage folate
release.
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from each specimen aa described. Extraction, assay and
calculation of results were as described.
RESULTS>
The percentage folate values obtained for the 10 blood
specimens are shown in Table 10. They are arranged as in
Series A except that groups 1, 2, 4 and 8 comprise 10
haemolysatea each while the remaining groups contain 7
haemolysates each. The mean and standard deviation were
calculated for each group and tests of significance applied
to compare the means in a similar way to that described for
Series A; The results are shown in Table 11.
The mean haeaolysate pH values ranged from 7.29 in the
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COMMENT:
Examination of the results in Table 10 shows that
the folate and pH values exhibit a trend differing from
that observed for Series A. (Table 8). It may thus be more
informative to analyse the results of the present series
by comparing them to those of Series A*
Table 12 compares the mean haemolysate pH values and
the mean folate release percentages obtained for both series
at different ascorbic acid concentrations.
It can be seen (Table 12) that there is a progressive
fall in haemolysate pH in both series with increasing ascorbic
acid concentration but that for a given ascorbic acid concen¬
tration the fall in pH is greater in Series B than in Series A.
The lower pH values in Series B. may be explained by the fact
that since a blood dilution of 1/10 contains a larger volume
of ascorbic acid solution per unit volume of blood than a
dilution of l/5» it follows that at any given ascorbic acid
concentration the buffering capacity of blood has to counter¬
act more hydrogen ions in the former case thus giving a
lower pH value them in the latter case.
Folate release:-
At ascorbic acid concentrations of 22.5» 45 and 90mg.%,
folate release is significantly higher in Series 8. than at
comparable concentrations in Series A. namely 20, 40 and
80mg.%/
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SOmg,% respectively. The folate percentages obtained
in Series B. at 22.5 and ^5®g*% ascorbic acid are also
significantly higher than those occurring in Series A. at
ascorbic acid concentrations of kO and 80mg.% respectively
(P < 0.05 and 0.005 respectively).
On the other hand a close relationship is shown
between haeraolysate pH and folate release irrespective of
ascorbic acid concentration. Thus in Series A. the pH of
6.9 and the percentage folate release of 63 found in the
presence of 80ag.% ascorbic acid are virtually identical
to the pH and folate values occurring in Series B. at
22.5»g*%t namely 6.87 and 6l% respectively. Similarly
the percentage folate yields at a pH of 5*84 in group 5 of
Series A. (200mg.% ascorbic acid) and a pH of 5.83 in group
k of Series B. (90mg.% ascorbic acid) are identical.
These findings indicate that pH alone irrespective
of the haemolysate dilution or ascorbic acid concentration
may profoundly influence folate release. By neglecting
the ascorbic acid concentration in both series therefore and
relating folate yield as a sole function of haemolysate pH,
a partial assessment of the role played by the latter on
folate release may be obtained.
This is shown in Figure 2 where the mean percentage
folate release in both series is plotted against the



























=i Series A ( \ Haemolysis)
Series B ( Jf0 Haemolysis)
Groups 1 to 8 from Left to Right.
The mean percentages of folate obtained at differing
ascorbic acid concentrations for Series A. (Table 8)
and Series B. (Table 10J are plotted against the
corresponding mean haemolysate pH. Group Wo. indicate
ascorbic acid concentration. (See Tables
63
that folate release is closely related to pH thus:-
(i) A gradual rise in folate release which is clearly
dissociated from ascorbic acid concentration occurs
between pH 7.4 and 5»8» All folate values occurr¬
ing at & pH of 5.8 and less are persistently over
94#.
(ii) The previously mentioned similarities between the
two series in folate yield at pH values of 6.9 and
5.8 are clearly shown.
(iii) A pH of 6.63 (occurring in group 3 of Series B.),
which has no counterpart in Series A., gives a
percentage folate release that is intermediate
between the values obtained at pH 6.9 and 5*8
respectively.
CONCLUSIONS.
These observations suggest that a pattern of
folate release as obtained from Series A. and B. may be
due entirely to the pH change rather than to a direct
effect conditioned by the presence of ascorbic acid.
For such a conclusion to be reached, however, ascorbic
acid must if possible be excluded from the system and
folate release assessed in a series of haemolysates
covering a similar pH range artificially adjusted with
H<S1 or Na<QH. If under such circumstances folate release
is found to conform to the pattern found in the presence
of/
6k,
of ascorbic acid, a MpureM pH effect secondary to the
presence of ascorbic acid can then be deduced as responsible
for the folate results observed for Series A, and B,
Experiments designed on these lines to investigate
the effect of pH on folate release will now be described.
65.
SECTION II.
THE EFFECT OF pH ON FOLATE RELEASE.
PRELIMINARY EXPERIMENT.
An initial study was made on the effect of pH on the
folate content of whole blood haemolysates. This was designed
with two purposes s-
1. To assess folate release in haemolysates prepared at
various pH values without ascorbic acid and to compare the
results with:-
2. Folate release in haemolysates prepared in ascorbic
N
acid solutions of 25 and 100rag.% respectively with added ^ NHC1
to give final haemolysate pH values comparable to those in (1).
METHOD:
Three sets of haemolysates were prepared from each of
N
two blood specimens in ^ NHC1 containing deionised water, 25mg.%
and 100mg.% ascorbic acid solutions respectively, as follows I-
9 ml. of deionised water or ascorbic acid solution
were added to each of 10 sterile universal containers followed
by appropriate volumes of — NHC1 (Appendix A5). 'Hie bottles
were shaken and 1 ml. of each blood sample added to each of
15 universal containers (with the three different haemolysing
fluids). The 1/10 haemolysates were thereafter treated as in
Series A. and B. i.e. 10 minutes at room temperature, 1 hour
at -20°C. followed by 1 hour at room temperature. pH
determination/
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determination, extraction and assay were as described.
An "optimal" folate release preparation was included
simultaneously for each blood specimen.
RESULTS:
Table 13 (A. and B.) relates percentage folate release
in both samples to the three pE ranges. Haemolysate No.5
in each case was prepared without the addition of HC1 and there¬
fore the pH and folate values here should be comparable to the
ap; ropriate values in Series B. (1/10 haemolysates) Table 12.
1. It can be seen from Table 13 that in the absence of
ascorbic acid folate release was 100% at pH 5»0 in Sample I
and 94% at pH 5*1 in Sample II.
2. In the presence of 25mg.% ascorbic acid, a reduction
in haemolysate pH to 3.3 - 4.9 was paralleled in both samples
by a marked increase in percentage folate release to values
ranging from 92% to 102%. At pH 3*0 however, folate release
is only 67% (Sample I).
3. The very low folate values obtained in the absence of
ascorbic acid at pH 4.1 and less (both samples) are in marked
contrast to those obtained at comparable pH values in
haemolysates containing 25rag.% ascorbic acid. Thus while
folate yields of 97% or more were obtained at pH 3»3, 3»5 and
4.0 (Sample I, 25mg.% ascorbic acid) only 2%, 4% and 33% were
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was done oyer a comparable pH range in the absence of ascorbic
acid. For a 100mg.% of ascorbic acid "maximal folate release
is maintained within a pH range of 3-6.
CONCLUSIONS.
These preliminary results supported the presumptive
evidence discussed previously that folate release is largely
pH dependent. The statement is, however, only true for pH
5.0 and 5.1 where "maximal" folate release occurred in the
absence of ascorbic acid. At lower pH values, the presence
of ascorbic acid seems to be important for either the
protection or release of folate. Folate release over a more
detailed pH range has been studied and the results shown in
the next series of experiments.
69.
A DETAILED STUDY OF THE EFFECT OF pH
OK FOLATE RELEASE.
These experiments were designed on similar lines to
the previous one except that wider and more detailed pH ranges
were covered.
METHOD:
1. Folate release was assessed within the following
pH ranges
Wo. pH range. Haeaolyaing fluid
+ HC1 or NaOH.
1 2.8 - 9*0 Deionised water.
2 2.3 - 7.6 25»g«% ascorbic acid
3 2.3 - 9.0 100 « » "
2. The pH was adjusted by adding either HC1 or NaOH to
the haemolysing fluid in a universal container prior to the
addition of blood (the quantities of HC1 or NaOH required to
be added for obtaining the various haemolysate pH values
are shown in Appendix A5).
3* Folate release was assessed at pH intervals as close
as possible, usually 0.2 - 0.3 apart, within each pH range.
To achieve this the following experiment was done using 5
blood specimens each with an approximate volume of 60 ml. and
a packed cell volume of 30% + 2#:-
(a) A series of haemolysates was prepared from each sample
to cover -























The release of folate at various pR values is the
abaenee of asoorbio sold (HC1 or NaOH was added to
water prior to addition of blood).
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10 - 15 pH values in range II (25»g.% ascorbic acid).
12 - 15 pH values in range III (lOOmg.% ascorbic acid),
(b) By preparing the three sets of haemolysates of a
given blood sample at slightly different pH values to
those obtained for the preceding sample, it was possible
to cover each pH range and therefore folate release at
0.2 - C.J intervals.
4. It was only possible to analyse one sample per day.
5. Haemolysis was at & blood dilution of 1/10, and all
haemolysates were treated by freezing and thawing as for
Series A, and B.
6. An optimal folate release preparation was assayed
concurrently with each blood sample as described previously.
7. Extraction, assay and calculation of the results were
as described.
RESULTS:
Folate release in pH range I (no ascorbic acid):
75 folate results were obtained from the five blood
samples investigated within this pH range. These are plotted
individually against their respective pH values in Figure 3*
For convenience the folate values were grouped at 0.4
pH intervals and the mean calculated for each group. The
histogram in Figure 4 relates the mean folate values,
calculated in this way over pK intervals of 0.4.
The scatter diagram in Figure 3 shows almost 100%
























2-6 30 U 3-8 4-2 4-6 50 U 5-8 6-2 6-6 70 H 7-8 9 0
pH
The means of the folate values in (Figure 3)
calculated at 0.^ pH intervals.
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almost no assayuble folate at pH 3.0. At pH 9 the folate
yield ranges from 25 - 39%. These features are shown in the
mean percentage folate yield plotted in Figure 4.
Folate release in pH range II (25ar,% ascorbic acid)•
The scatter diagram in Figure 5 demonstrates a change
from the previous situation in that maximal folate release occurs
within the pH range of 3.1 - 6.1. A sharp fall in folate yield
is shown at pH values of less than 3.1 and a more gradual one
at pH values of more than 6.1. These findings are substantiated
in Figure 6 where a mean percentage folate release of 90 - 96
is found for the pK range of 3.1 - 5.8. A slight drop to
85% occurred for the pH interval (5.9 - 6.2).
Folate release in pH range III (100mg.% ascorbic acid).
The 64 results results are presented in a similar
manner in Figures 7 and 8 respectively.
The pattern for folate release is similar to that in
pH range II, the highest values occurring within the pH range
of 3.1 - 6.1.
COMMENT:
The results in Figures 3 and 4 show that a
modification of pH alone affects folate release. The maximal
effect is in the pll range of 4.8 - 6.1. Such a range must
represent the pH optimum for folate release in haemolysates
prepared in the way described (no ascorbic acid).
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25 mg °1o Ascorbic Acid
No Ascorbic Acid
The pH-folate release pattern in the absence of
ascorbic acid compared to that obtained in the
presence of 25»g.% ascorbic acid.
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to enhance folate release or stability at a more adid pH
namely k,6 - 3.1. There is no significant difference in
folate release, at any of the pH intervals, between experiments
where either 25 or lOOmg.% ascorbic acid was used (Figures 6
and 8).
Comparison between folate release in pH range I. (no ascorbic
acid and pfl range II (25mg.%)«
The results obtained within the two pH ranges are shown
together in Figure 9»
in the pH range k.7 - 7 the two sets of results are
indistinguishable. At a more acid pH than ^.7, however, much
higher folate values are obtained if ascorbic acid is present
in the haemolysates.
The possible causes of the discrepancy in folate yield
at acid pH between the two systems may be one or both of the
following
1. Ascorbic acid may be essential for the protection of
folate released at low pH values. Folate is known to be
unstable at extremes of pH but more so at acid than alkaline
pH.
2. Ascorbic acid may be protecting or potentiating the
plasma factor action at low pH values.
Experiments investigating the stability of "released
folate" at various pH values in the absence of ascorbic acid
will now be described.




1. 135 ml* of dcloniced water were delivered into a
sterile J'RC bottle, to which NHCl was added, followed by 15 ml*
of blood (P.C.V. 30%). The final haemolysate volume was
150 ml. and its "expected" pH 5*0 £ 0.2 (Appendix A5)*
2. After 10 minutes at room temperature the haemolysate
was subjected to freezing and thawing as described*
3* ml. were then extracted to determine folate release.
This is "control Ko.l", being the haemolysate*s "basal" folate
content. pH determination was done on a small aliquot.
k, To determine the effeot of pH on folate stability, the
haemolysate was treated as follows»-
(a) 10 ml. aliquots were added to 10 sterile universal
containers. HS61 or N haOH was added to each to give
haemolysate pH values ranging from 3-11*
(b) 5®g* of ascorbic acid were added to 20 ml. of the
original haemolysate and the pH brought to 3*5 by adding
HHC1. This is control Ho. 2 where the pH is lowered
in the presence of ascorbic acid. All universal
containers were subjected to freezing and thawing again
as described.
pH determination was carried out on each haemolysate.
Extraction end essay were as described.
An optirrel folate release was done as described.
Rrsm TS:
The percentage of folate recovered after readjusting





Y////////A Folate remaining after readjusting the pH.
Original Folate content of haemolysate.
I i pH lowered in presence of 25 mg 70 of ascorbic acid.
The percentage stability of released folate determined
at various pH values, in the absence of ascorbic acid.
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and Figure 10 with the original heemolyaate folate content and
the amount obtained when the pH was lowered in the presence of
25mg.% ascorbic acid.
TABLE (1*0.
pH 3.2 3.4 3.8 4.0 4.6 5.2* 7.1 9.7 10 10.9 11.3 3.5X
% folate
recovered.
16 17 24 28 76 100 102 103 103 88 69 102
Percentage folate stability at various pH values.
* Control I (original haemolysate pH).
x Control 2 (pH lowered in presence of 25»ng.%
ascorbic acid).
COMMENT:
The original haemolysate had a pH of 5.2 which is within
the optimal range for folate release. It was found to have a
folate content of 102% as given by control No.l (Table 1^).
When the haemolysate pH was readjusted over a wide range,
a marked loss of folate occurred at low pH values. Thus when
the haemolysate pH was dropped to 3»2, 85% of its folate was lost.
On the other hand, folate seems to be reasonably stable
when exposed to alkaline pH. It is completely stable for
example up to a pH of 10 and possibly more. Evan at a pH of
11.3 the folate loss is only 31%.
Of especial interest is the complete protection of
folate when 5mg. of ascorbic acid was added immediately before




1. Histogram = "pH - folate release pattern" in the absence of ascorbic acid —» I = t one SD.
2. vzzzzzzzn V, of folate remaining after readjusting pH.
3- i I ( Control H?2.) pH lowered in presence of 25 mg 7. ascorbic acid
I. bmi Original haemolysate folate content I Control H* 1)
Comparison between percentage folate release and stability
patterns determined at various pH values in the absence of
ascorbic acid.
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which proves that ascorbic acid has a protective effect for
folate at low pH values.
The percentage folate stability and the release
patterns obtained at various pH values in the absence of
ascorbic acid are shown together in Figure 11.
It is clear from the figure that at comparable pH
values and within a pH range of 3.1 - 5.2 the "release" and
stability patterns are closely matched. This suggests that
the low percentage folate "release" found within the pH range
3*1 " 4.6 reflects folate instability rather than reduced
plasma factor action. The fact that ascorbic acid has been
shown to protect folate at low pH values explains the discrepancy
in folate "release" between pH ranges No. I and II observed at
pH values less than 4.6 (Figure 9).
At higher pH values (more than 6.2) on the other hand,
where folate is shown to be fully stable, a suboptimal enzyme
action must be responsible for the lower percentage folate release.
The effect of modifying the pH on the folate yield of
haemolysates containing 900ing.% ascorbic acid:
When haemolysis was carried out in the presence of
25 and 100mg.% respectively maximal folate release occurred
within a pH range of 3»1 - 6.1 (Figures 5 and ?)•
In order to see whether a higher ascorbic acid
concentration would alter this pH range, haemolysates were
prepared from 4 blood samples in lg.% ascorbic acid solution,
to/
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to which either HC1 or NaOH was added to give haemolysate
pH values distributed about the range of 3.1 - 6.1.
Samples were haemolysed at a blood dilution of l/lO
and treated by freezing and thawing a3 described. The
haemolysate ascorbic acid concentration was 900mg./S.
Extraction, assay and calculation of results were as
described*
B3SPLTB:
The results are shown in Table 15 as percentages of
optimal folate release against the appropriate haeraolysate
pH values. Folate release is "suboptimal" in all samples
and comparable to that obtained in the presence of 25mg.%
ascorbic acid at similar pH values (Figures 5 ana 6). This
indicates that raising the ascorbic acid concentration to
900mg.% does not alter the pH range for "maximal" folate














1 2.9 60 6.8 5**
2 2.8 57 6.8 61
3 2.6 20 7.0 29
k 2.6 19 7.0 3^
Folate release at different pH values in haemolysate





























62 "7 7 0 7-4
1 - Histogram = "pH -Folate release pattern" in presence of 25mg 7o ascorbic acid*I = SD.
2 - T Series "A" ( Haemolysates) mean folate release ± one SD.
3 - j Series "B"( /n Haemolysates) mean folate release 1 one SD.
Comparison between the effect of ascorbic acid
concentration and pH on folate release.
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Comparison between the effect of ascorbic acid concentrations
and pH on folate release.
No significant difference was shown when the mean percent¬
age folate values of haemolysates containing 0 - 900mg.%
ascorbic acid (Series A. and B.) were compared with those
obtained at comparable pH values but in the presence of 25®g»%
ascorbic acid. This is illustrated in Figure 12.
To exclude the possibility that the use of different blood
samples in experiments investigating the role of ascorbic acid
or pH on folate release may have influenced the results shown
in Figure 12, a large blood specimen was obtained from a single
donor and haemolysates prepared from the sample by the methods
described previously, namely:-
1. 1/5 haemolysates containing 0 - 800rag.% as in Series A.
2. 1/10 haemolysates containing 0 - 900mg.% as in Series B.
3« 1/5 haeraolysates prepared at pH values comparable to those
in (1) but containing 25®g.% ascorbic acid.
4. 1/10 haemolysates prepared at pH values comparable to those
in (2) but containing 25®g*% ascorbic acid.
The folate content of haemolysates was determined and
calculated as described and related in Figure 13 to pH.
The findings are the same as in Figure 12 in that it is
the pH and not the ascorbic acid concentrations which determines
folate yield.
THE EFFECT OF pH ON FOLATE RELEASE























5-0 5-5 6-0 6-5
pH
* ho —* Haemoylsis in 0-1g°7o Ascorbic acid
o
x ho 11 25 mg 7. Ascorbic acid ( pH adjusted
Comparison between the effect of ascorbic acid
concentration and pH on folate yield in a single blood
saople.
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To determine the effect of varying the pH in the
absence of plasma on the release of assayable folate from
erythrocytes.
METHOD:
A 20 ml. hepariniaed blood sample was centrifuged,
plasma removed and the red cells washed four times in acid
citrate dextrose (ACD) by centrifugation for -J hour at 3000g.
each time. Care was taken to remove as completely as possible
the supernatant ACD after each wash.
Using the same method for whole blood (p. 70), six
haemolys&tes containing 25mg.% ascorbic acid were prepared
from the washed cells at a dilution of 1/10 and within a pH
range of 3.0 - 6.0.
A control was included where the cells and plasma were
recombined, the P.C.V. determined and the sample haemolysed
at pH 3.7» All haemolysates were froeen and thawed, extracted
and assayed as described.
RESULTS t
The folate content of the washed erythrocytes
determined at the various pH values was expressed as a
percentage of the value obtained (mug/ml. packed cells) for
the control (cells + plasma). The results are shown in
Figure 1'f.
It is clear from Figure 14 that washed erythrocytes
yield negligible amounts of folate under these circumstances.




























The effect of modifying the pH in the absence of
plasma on folate release from washed erythrocytes
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and is less than 10% of that obtained for whole blood,
indicating that the release of maximal folate from erythrocyte
at all pH values depends on the presence of plasma.
CONCLUSIONS.
The results of the experiments in Sections I and II
indicate that:-
1. Maximal release of assayable folate from erythrocytes
occurs within a much wider pS range (5.1 * 6.1) than
previously reported and that the presence of 25®g«%
ascorbic acid or more is important for maintaining the
released folate in an assayable form.
2. Folate release is plasma dependent at all pH values.
SECTION III
THE EFFECT OF TEMPERATURE AND HAEMOLYSIS
ON FOLATE RELEASE.
EXPERIMENT I.
Previous experiments (Section I, Series B.) had shown
that folate yield was "suboptimal" when whole blood haemolysates
prepared at a dilution of 1/10 by freezing and thawing contained
ascorbic acid concentrations ranging from 0 - 45mg.%. The
present experiment was designed to determine whether incubation
at 37°C. would alter the folate yield of such haemolysates.
METHODi
Duplicate haemolysates were prepared at a dilution of
1/10 from each of six blood specimens in a series of ascorbic
acid solutions containing 0* 25» 30 and 100 mg.% respectively
as described in (Section I, Series £.). In this way four
pairs of haemolysates containing 0, 22.5» ^5 and 90mg.%
ascorbic acid respectively were obtained from each blood
specimen. k haemolysates representing the different ascorbic
acid concentrations were transferred after 10 minutes at room
temperature to an incubator at 37°C. for 90 minuteB. Their
duplicates were treated by freezing and thawing as described
for Series A. and B. (Section I).
An "optimal" folate release preparation was included





Table 16 compares the mean percentage folate release
obtained from haemolyeates prepared by incubation with that
obtained by freezing and thawing. At the various ascorbic
acid concentrations, the mean folate values obtained after
incubation did not differ significantly from those obtained
after freezing and thawing. Mean folate values of 95% or
more were obtained as expected in haemolysates containing
90mg.% ascorbic acid. These findings indicate that a
temperature of 37°C. is not an important requisite for folate









kl 62 76 97
37°C. for 90•
SD+ 8.9 e.k 10.1 k.S
Mean % folate
release after
freezing and 38 59 78 95
thawing SD+ 9 11.3 2 6.2
Mean percentage folate release in six blood
specimens after incubation at 37 C. compared
to that after freezing and thawing ih the




This experiment was designed to investigate the
factors influencing folate release in whole blood incubated
in phosphate buffer at 37°C. Toennies et al. (1956) had
reported an increasing folate yield with increasing incubation
time under such conditions and this he had attributed to an
enhanced plasma factor action. The technique adopted was
changed from that of Toennies and co-workers to determine
whether their haemolysis was complete. The modifications
Included
(i) The rate of haemolysis was determined concurrently with
that of folate release during the incubation time.
(ii) Preliminary experiments had shown that the folate
yield from a whole blood dilution of J/750 (used by
Toennies et al.) was too small for accurate measurement
especially at short incubation periods and hence a
1/500 dilution was adopted instead.
METHOD:
19*6 ml. of a freshly prepared 0.05 M phosphate
buffer pH 6.0 containing 50rag.% ascorbic acid were pipetted
into each of 21 sterile universal containers which were then
incubated at 37°C. for 15 minutes to effect temperature
equilibration.
0,0b ml. of a freshly drawn heparinised blood sample




0 05 m Phosphate buffer
Per cent
Time ( minutes)
Haemolysis o-—o Folate release
Percentage haemolysis and folate release determined at
▼arious periods during the incubation of whole blood in
•05 M phosphate buffer at 57 C.
96.
being 1/500. After each of the following incubation periods
0, 5« 10, 15, 30, 60 and 90 minutes three bottles were
removed from the incubator, shaken thoroughly and centrifuged
at 1500g. for 5 minutes and the supernatants pipetted into
clean containers. One of each of these containers was set
aside for measurement of haemolysis. The ascorbic acid
content of the remaining pair was adjusted to 200mg.% and
the samples extracted in the usual way.
The optical density of haemolysates was measured in
a Unicam calorimeter at 5^0 and the degree of lysis at the
various incubation periods calculated as a percentage of
that obtained after 90 minutes incubation.
Extracts were assayed in duplicate without further
dilution and their folate content calculated as a percentage
of that of the sample incubated for 90 minutes.
RESULTS:
The relation between percentage haemolysis and folate
release is shown for different incubation periods in Figure5l5«
EXPERIMENT III.
OBJECT?
To determine the rates of haemolysis and of folate
release in whole blood at room temperature when the pH is
varied over the optimum range (pH 3.1 - 6.1).





1. THE HATE OF FOLATE RELEASE.
A. At pH 3.6:
(i) Using lg.% aqueous ascorbic acid solution
13j ml. volumes of a freshly prepared lg.% ascorbic acid
solution were dispensed into each of 3 sterile universal
containers. To each was then added 1-J ml. of a different
blood specimen giving a blood dilution of 1/10 and a
haemolysate ascorbic acid concentration of 900mg.%. The
contents of each bottle were mixed and left at room temperature.
2 ml. aliquots were then removed from each bottle after 5,
10, 15 and 30 minutes respectively, added to 18 ml. of 0.1 M
phosphate ascorbate buffer and extracted by immediate auto-
claving.
An optimal folate release preparation was prepared
simultaneously from each blood specimen.
(ii) Using 100mg.% ascorbic acid solution adjusted for
pH 3.6 with HC1
Two separate blood specimens were haemolysed in this
solution at a dilution of 1/10 and folate release timed in
exactly the same manner as in (i). The haemolysate ascorbic
acid concentration was 90mg.%.
B. At pH 5.8:
Using 100mg.% ascorbic acid solution
The two blood samples from A (ii) were used and folate
release timed as in A (i) and (ii).








5 10 15 30
Sample
No.
Folate % of optimur 1.
1 kk 100 00ON 102
2 86 9k 95 97
3 70 96 98 99
The rate of folate release at room
temperature using lg»% aqueous ascorbic
acid solution pH 3.6.
TABLE (18).
Sample I. Sample II.





5 52 3k 62 25
10 99 k7 102 31
15 97 66 95 38
30 100 78 96 k7
The rate of folate release at room
temperature using 100mg.% aqueous ascorbic
acid solution (pH 5.8) and adjusted with
HC1 (pH 3.6).
99
With one of the blood specimens used in A. (ii) and
B-, the rate of haemolysis was determined using the two
haemolysing solutions (100mg.% ascorbic acid solutions pH
3.6 and 5*8 respectively).
METHOD:
3.8 ml. of each solution were pipetted into each of
6 tubes and paired. 0.2 ml. of blood was then added to each
tube and after 5» 10, 15 and 30 minutes at room temperature
a pair of tubes was centrifuged for 3 minutes at 1500g. and
the eupernatants pipetted into clean tubes. The 6th pair
was frozen at -20°C. for 1 hour then thawed at room temperature
and their supernatants taken to represent 100% lysis for the
appropriate pH value. Ilaemolysates were diluted 1/200 with
water before reading in a Unicam colorimeter at 5^0•
RESULTS:
1. Table 17 shows the rate of folate release at room
temperature and pH 3.6 in haemolysates containing
900mg»% ascorbic acid.
2. Table 18 compares the rate of folate release at pH
3.6 and 5*8 respectively at room temperature in
haemolysates containing 90mg.% ascorbic acid.
3. The rates of haemolysis and folate release at both














• • Haemolysis at pH 3-6
A A Haemolysis at pH 5-8
O o Folate release at pH 3-6






The rates of haemolysis and folate release determined
at pH 3.6 and 3*6 at room temperature*
101.
COMMENT;
Figure 15 shows that when whole blood is incubated
at 37°C. in 0.05 M phosphate buffer, haemolysis, incomplete
initially, increases markedly with time during the first 30
minutes and thereafter very slowly up to 90 minutes. This
implies that the folate release pattern in this experiment
is markedly dependent on the rate of haemolysis as well as
on the plasma factor-substrate interaction. From the
figure it is also clear that plasma factor action develops
more slowly than the degree of haemolysis.
In contrast, Table 17 shows that maximal folate
release occurs within 10 minutes at room temperature when
1/10 haemolysis was carried out in lg.% aqueous ascorbic
acid solution. That this is largely a pH phenomenon is
shown in Table 8 where similar folate results were obtained
in haemolysates at the same pH (3*6) but containing 90mg.%
ascorbic acid instead. Figure 16 shows that whereas rapid
haemolysis occurs at both pH values, the rate of folate
release at pH 5.8 is much slower than at pH 3.6, a finding
which suggests that folate is released at a variable rate
within the optimum pH range 3.1 - 6.1. The implications
of this will be discussed later.
CONCLUSIONS.
The results of these experiments indicate
(i) Providing that whole blood is adequately haemolysed
in/
10P.
in water, incubation at 37°C. is not required
for the release of assayable folate from
erythrocytes. Toennies observations (1956) were
explained by the initial incomplete haemolysis in
.05 M phosphate buffer and its enhancement with
increasing incubation time.
(ii) "Maximal" folate yield can be obtained within a
short period at room temperature by haemolysing




THE "FOLATE RELEASING PROPERTIES" OF PLASMA
IN HEALTH AND DISEASE.
The ability of plasma to release assayable folate from
washed erythrocytes was studied in the following groupsj-
(a) 32 normal subjects*
(b) 19 megaloblastic vitamin deficient patients.
(c) 19 " folate " "
(d) 23 cases of rheumatoid arthritis.
The details of the patients are shown in Appendix (C»).
The investigations comprised two parts»-
Part Ii-
Folate release was compared in each group when the
washed erythrocytes of each subject were combined in turn with:-
(i) A "control" plasma (supplied by the same donor
throughout the study) and used for all cases
investigated*
(ii) The subject's own plasma*
Part lit-
Differing quantities of pooled plasma (0*05-0*Ami*)
obtained from each group were combined with aliquots of a
normal haemolysate each equivalent to one ml* of washed packed






Heparinised blood samples were obtained from the same
donor every weeks. Plasma was separated, divided into 1.3 ml.
aliquots, and stored at -20°C. without ascorbic acid in sterile
universal containers.
(b) Collection of blood from subjectst
kO ml. were obtained by venepuncture from fasting
subjects. 2 ml. were delivered into a sequestrene bottle for
determination of the haematological indices, 18 ml. into a
universal container and allowed to clot for 2 hours at room
temperature, before serum was separated and stored at -20°C. for
vitamin estimation. The remaining 20 ml. were added to a
heparinised universal container from which plasma was separated
by centrifugation at 3000g. for 30 minutes and then divided into
three aterile universal containers and stored at -20°C. as follows:
(i) k ml. with lOag. of dry ascorbic acid per ml. for
folate estimation.
(ii) 1.3 ml. without ascorbic acid to be recombined
2-3 hours later with the subjects washed
erythrocytes.
(ill) The remainder was stored for other studies.
(c) Preparation and storage of whole blood samples:
The packed cells were washed three times with acid
citrate dextrose (ACD) by centrifugation at 3000g. for 30
minutes. Two universal containers with 1.5 ml. aliquots of
"control" and "subjects plasma respectively were thawed at room
temperature and 0.8 ml. of the washed packed cells added to each.
The samples were mixed thoroughly and their micro¬
tiaema toorit/
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microhaematocrit values determined. The P.C.V. ranged from
27-30%. 0.4 ml. of each sample was then pipetted into each
of three sterile universale containing 10mg. of dry ascorbic
acid. The bottles were shaken thoroughly to dissolve the
ascorbic acid and stored at -20°C. until extracted.
1.5 ml* of "control" plasma to which 15ag. of ascorbic
acid had been added was stored with each batch of samples for
folate estimation.
(d) Extraction of whole blood folatei
25-30 samples were extracted at a time. For each
sample two bottles each containing 0.4 ml. of blood (one with
"control" and the other "subject's" plasma) were thawed at
room temperature. 1.6 ml. of deionised water were then added
to each, the contents mixed and left at room temperature for
15 minutes followed by the addition of 18 ml. of 0.1 M phosphate
buffer containing 150mg. per cent ascorbic acid. The final
blood dilution was 1/50 and the final ascorbic acid concentration
200mg. per cent.
The samples were autoclaved for 5 minutes at 15 p.s.i.
and the extracts stored at -20°C. until assayed.
Each sample was extracted at least twice and independent
assays were performed on the extracts. The mean folate value
of these was expressed as mug/ml. of packed cells as described
in Appendix B2.
Part II:-
Haparinised blood samples (20 ml. each) were obtained
from/
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from 4 normal subjects. The packed cells were washed four
times by centrifugation in ACD at 300|pg for 30 minutes
taking care each time to remove as completely as possible the
supernatant ACD.
30 ml. of the pooled washed cells were added to 270 ml.
of a g. per cent ascorbic acid solution contained in an MJRC
bottle to give a 1/10 dilution and the haemolysate frozen and
thawed as described. 10 ml. volumes (si ml. of packed cells)
were dispensed into each of 23 sterile universal containers.
The following quantities of "control" and pooled plasma
obtained from each of the groups under investigation were
added successively to each of six universals containing the
haemolysate t-
0.05 0.1 0.15 0.2 0.3 0.^ ml.
A "control" haemolysate with no plasma was included.
All bottles were transferred to an incubator at 37°C.
and 30 minutes later extracted and assayed in duplicate as
described and the folate content of each haemolysate
expressed as mug/ml. of packed cells.
RESULTS.
1. Effect of storage on "the folate releasing ability" of
plasma:
Four samples of washed erythrocytes were combined with
"control" plasma that had been subjected to various periods of
storage at -20°C. and Vc. respectively and folate release
assessed. The results in Table 19 which are expressed as
percentages/
10?.
percentages of folate release by fresh plasma, show that
storage up to a period of 4 months at 4°C. and 4J months at
-20°C. does not affect the folate releasing properties of
human plasma.
TABLE (19).
Period and temperature of storage.
Fresh
-20"C. + 4"C.
2/52 3/52 4J/12 4/12
Washed RBCs.
Sample No*
% Fola ;e yield.
1 100 109 93 106 106
2 100 96 99 110 97
3 100 - 100 106 94
4 100 - 108 95 103
Folate release by "control" plasma after different
periods of storage at -20 C and-t-4 C expressed as %
of that released by fresh plasma.
N.B. The "control" plasma is the same as used for
folate release in the study.
The effect of storage at -20°C. on whole blood folate I
The folate levels of 12 blood samples prepared in the
way described in Part I. were estimated before and after storage
with ascorbic acid at -20°C. for 3 months. The results are
shown in Table 20 as percentage rise or fall in folate content
after/
108.
after storage. The folate levels obtained after 3 months
were not significantly different from the initial values
P<0.5.
TABLE 20.
Blood specimen % Hise or fall in to.B. folate after













t = d « 0.6897
I / var.(d)
v ~ (p < 0.5)
The effect of storage on whole blood folate.
* Appendix B1•
Comparison between folate release by "control" and "subject's"
plasmat»
Part 1
The folate values (mug/ml. packed cells) obtained by














Total No. 32 19 19 25
Serial No. A B A B A B A B
1 228 230 36 35 166 159 120 105
2 184 183 37 25 163 147 183 160
3 164 155 112 105 108 103 103 111
if 245 279 - - 247 250 209 198
5 156 145 50 43 171 168 121 112
6 160 143 37 38 204 181 88 70
7 178 161 32 34 49 45 194 166
8 149 143 30 24 148 146 290 305
9 195 190 98 83 213 202 282 255
10 147 140 24 23 - - 199 177
11 170 185 61 60 98 88 225 179
12 190 186 32 31 151 155 251 215
13 185 164 42 40 88 79 189 150
14 199 170 99 98 130 150 109 117
15 150 162 - - 188 179 175 130
16 159 177 53 55 61 57 109 91
17 175 186 - - 105 99 163 131
18 166 167 24 26 148 153 136 118
19 175 184 - - - - 163 164
20 151 152 51 54 104 115 172 169
21 225 195 40 43 50 54 208 188
22 168 152 130 132 - - 259 259
23 146 147 23 26 - - 135 129
24 170 167 - - - - 304 263
25 239 235 - - - - 208 188
26 269 231 - - - - - -
27 200 176 - - - - - -
28 238 240 - - - - - -
29 129 138 - - - - - -
30 186 204 - - - - - -
31 152 174 - - - - - -
32 168 186 - - - - -
Nun 182 179 53 51 137 134 183 166
SD t 34 34 32 31 56 55 61 59
The erythrocyte folate values (mug/ml.) obtained in each
group by the use of "subjects" and "control" plasma against
subjects erythrocytes.
110.
subject's erythrocytes are detailed for each group in Table 21.









Bo of cases. 32 19 19 25
t 0.2837 1.7250 1.4936 4.9016
P 0.8 0.1 0.1 0.2 0.001
The significance of tho difference in folate
release by "control" and "subject's" plasma in
each of the four groups studied.
Part II
Figure 17 compares the folate release patterns
obtained when differing quantities of either "control" or
pooled plasma from the three groups of patients were combined
with a constant haemolysate volume.
COMKEBT.
Table 22 shows that folate release by normal plasma






































a » folate deficient plasma
en .
• '■ B12 " "
□U
x " rheumatoid arthritis plasma
1 ' s Washed Erythrocytes
25-
0-05 0-1 0-15 0-2 0-3 0-t
ml. of Plasma
The folate release patterns obtained when differing
quantities of either "control" or pooled plasma from
the three groups of patients were combined with a constant
volume of haemolysate prepared from washed normal
erythrocytes.
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erythropoiesis is not significantly different from that
obtained by the uae of "control" plasma. Release by
rheumatoid plasma on the other hand is significantly reduced
when compared to control plasma P<0.001. Thus in four cases
(11, 13, 15 and 17) in the latter group (Table 21), folate
release by the patient's plasma is leas than 85% of that by
control plasma and in two of these namely Cases No. 15 And
17, the use of the patient's plasma brought down the erythrocyte
folate content to deficiency levels (less than 135«aug/nl.
packed cells). These findings indicate that in rheumatoid
arthritis, the plasma folate releasing ability is reduced to a
variable extent and that in some cases the low erythrocyte
folate levels resulting from the use of whole blood obtained
from such patients may be indicative of a reduced plasma factor
action rather than a decrease in the erythrocyte folate precursors.
The Vitamin and folate deficiency states on the
other hand do not seem to alter significantly the plasma foists
releasing characteristics.
When differing quantities of "control" or pooled plasma
(from the three disease states) were combined with a constant
volume of normal haemolysate, similar folate release patterns
were obtained (Figure 17).
The "release curves" overlap at various points and
there was no significant difference between the folate yield by
the four plasmas at any of the volume® used. This is at
variance with the finding (Tables 21, 22) that a lower folate
yield/
113.
yield is obtained by recombining plasma and erythrocytes




The effect of ascorbic acid and pH on folate release;
When the release of assayable folate was assessed
in two series of haemolysates containing differing quantities
of ascorbic acid and in both of which complete haemolysis was
ensured by freezing and thawing, it. was found that the
"maximal" yields occurred at ascorbic acid concentrations
of 90mg.% or more when the blood dilution was 1/10 and 200rag.$
or more in haemolysates prepared at a dilution of l/5»
Further, at comparable ascorbic acid concentrations
folate release was significantly higher in the 1/10 than the
1/5 haemolysates. Analysis of the results showed that
these dissimilarities in folate yield were due to different
pH patterns in the two series of haemolysates. Thus for
a given ascorbic acid concentration the pH was lower at the
higher blood dilution! also irrespective of ascorbic acid
concentration or blood dilution similar folate values were
obtained at similar pH values. This suggested that ascorbic
acid might influence folate release by virtue of its
acidifying effect rather than by a direct action on the
folate releasing mechanism. In terms of pH the maximal
folate values in these haemolysates occurred within a range
of 5*8 to 3*6. The concept of a "pH" effect was partly
supported by finding that a modification of pH alone with
HC1 in the absence of ascorbic acid markedly affected
folate release. Under these circumstances "maximal" folate
release/
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release occurs within a pH range Of 4.7 to 6.0 with very
little measurable folate at pH values less than 4,0.
When haemolyeates were prepared at similar pH values but
made to contain 25®g*^ ascorbic acid as well, maximal amounts
of folate were released within a much wider pH range namely
3.1 to 6.1 (Figure 9). This discrepancy in folate yield
between the two experiments was explained by the extreme
lability of folate at pK values less than 4.7 and its
complete protection by ascorbic acid.
One is not aware of a reference in the literature
to the protective effect of ascorbic acid at low pH on
assayable folate. The underlying mechanism is bound to be
chemical and related to the preservation of the integrity of
5
the molecular configuration of the assayable N - methyltetra-
hydrofolic acid raonoglutamate.
A modification of pH alone in the absence of plasma
was ineffective in releasing folate from washed erythrocytes.
It would appear, therefore, that plasma is capable of
releasing assayable folate from erythrocytes maximally within
a pll range of 3.1 to 6.1 and that at pH values less than
4.7 ascorbic acid is needed for protecting the released
folate. The latter finding would explain why Toennies et
al. (1953), who did not include ascorbic acid in their
experiments, found that folate yield approached zero at pH
4.0 and that optimal yield was around pH 5.7. Even within
the optimal pH range 3.1 to 6.1 folate is apparently
released at a variable rate. Thus in two samples investigated
the/
116.
the amount of folate released after 10 minutes at room
temperature was 99% and 102% respectively at pH 3.6 as
compared to k7% and 31% at pH 5*8 (Table 18), This might
indicate that there is more than one plasma factor each of
which has different kinetics and pH requirements. The
possible multiplicity of the plasma factor had been suggested
previously by Toennies and Phillips (1959) who found that the
stepwise elution of a crude plasma factor preparation from
DEAE cellulose gave k fractions with different plasma factor
activities. On the other hand there may be only one enzyme-
substrate system which can, within its own optimum pH range,
reach equilibrium much more rapidly at lower than at higher
pH values. Folate is present inside the red cell as conjugates
8
of N -methyltetrahydrofolic (Noronha and Aboobaker 1963)# It
is not known for certain how or to what these precursors are
attached inside the cell although it has been suggested
that they may be protein bound (Iwai et al. 196^). As a
fall in pH alone in the absence of plasma does not release
assayable monoglutaraates from these conjugates, it is
possible that pH facilitates folate yield by releasing the
substrate from its binding inside the cell and so exposing
it to enzymatic action.
Incubation at 37°C.
The observations of Hoffbrand et al, (1966^ that
maximal folate release occurs in haemolysates prepared in
lg.% ascorbic acid solution without incubation at 37°C. has
been/
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been confirmed in these studies. The folate yields in
subsequent experiments have been assessed after freezing
and thawing and calculated as percentages of the folate
released after the incubation of haemolysates containing
900mg.% ascorbic acid for 90 minutes at 37°C. The occurr¬
ence therefore in these experiments, e.g. those investigating
the effects of ascorbic acid or pH, under optimal conditions
of mean folate values ranging from 90 to 99% indicates that
folate release after freezing and thawing is comparable to
that after incubation. Further incubation did not increase
significantly the "suboptimal" folate values obtained by
freezing and thawing haeaolysates containing 0 - 50mg.%
asoorbic acid. It would seem, therefore, that a temperature
of 37°C. is not an important requisite for folate release in
whole blood haemolysates prepared by the described methods.
The pattern of folate yield described by Toennies et
al. (1956) during the incubation of whole blood at 37°C. in
0.05 M phosphate buffer was partly explained by the initial
incomplete haemolysis of blood and its enhancement with
increasing incubation time. The 90 minutes incubation period
recommended by these workers for maximal folate yield i6 in
marked contrast to the few minutes required at room temperature
for such a release to occur when haemolysis was carried out
at a pH «rf 3.6 and a blood dilution of 1/10. The adoption
by Toennies et al. of a pH of 6.1 as well as an excessively
high blood dilution (1/750) may have, in addition to incomplete
haemolysis/
118.
haemolysis, contributed to the marked delay in reaching
the folate peak.
The choice of a method for whole blood estimation:-
The results of the study indicate that the method
described by Hoffbrand et al. (1966a) is to be preferred to
other published methods. In this method haemolysis is
carried out at low pK (approximately 3*6) and in the presence
of ascorbic acid both of which conditions have been shown to
cause rapid folate release. The authors had shown that
the folate content cf these haemolysatee is not affected by
storage for up to 5 months at -20°C.
SUMMARY.
The release of assayable folate from erythrocytes
occurs maximally within pH range 3*1 - 6.1. This
optimum pti range is much wider than previously reported.
In the absence of ascorbic acid the released folate
is extremely "labile" at pfi values less than 4.7*
Ascorbic acid concentrations of 25®g»% or mere afford
complete protection.
Folate is released much more rapidly at lower than
at higher pH values within the optimum pH range (5.1 *»
6.1). The possible causes of this are discussed.
A modification of pH alone i.e. in the absence of
plasma was not associated with the yield of assayable
folate from erythrocytes.
Incubation was found unnecessary for folate release
from erythrocytes even when tested at different pH values
or ascorbic acid concentrations. Explanations were
offered for the findings of Toennies et al. (1956).
Plasma from patients with megaloblastic erythropoelsia
is as efficient as normal plasma in releasing folatef
but folate release by plasma from patients with rheumatoid
arthritis is significantly reduced when compared to
normal.
The method described by lioffbrand et al. (1966,a)





Moderate anaemia of a hypochromic normocytic type
is a common feature of rheumatoid arthritis. Macrocytic
anaemia on the other hand has been reported less frequently.
Macrocytoeis was regarded as coincidental by Short, Bawer
and Reynolds (195?) or due to the use of anticonvulsant
drugs (Chanarin, Laidlaw, Loughridge and Mollin, I960).
In the study of the bone marrow of 6*» patients with
rheumatoid arthritis, Richmond, Gardiner, Roy and Duthie
(1956) found no consistent abnormality apart from a moderate
increase in plasma cells. Reviewing the literature, these
authors found that megaloblastic erythropoiesis had been reported
only once in patients with rheumatoid arthritis (Marmount 19**8)«
Partridge and Duthie (1963) found an incidence of macrocytic
anaemia attributed to vitamin deficiency in 1.38% of
25^ patients with rheumatoid arthritis as compared to an
incidence of 0.2?% in controls. Other authors (Forshaw
1963i Mollin, Waters, Gough and Read 1963) commenting on
this paper suggested that folate deficiency may have existed.
Gough et al. (196*0 in a study of *f6 patients with rheumatoid
arthritis reported that 65% had subnormal folate levels and
that in 33% the levels fell within the range encountered in
megaloblastic folate deficiency. The same study also
revealed that 6 of the patients had megaloblastic erythro¬
poiesis due to folate deficiency and that 73% of the patients
with/
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with subnormal serum folate levels excreted abnormal amounts
of FIGLU. Similar percentages of low serum folate levels
were reported by Dellar et al. (1966).
It was decided in the present study to undertake a
fuller investigation of the folate status in rheumatoid
arthritis. Various tests of folate deficiency including
erythrocyte folate levels were assessed in the rheumatoid
arthritis group. Comparisons were also made with the plasma
and erythrocyte folate levels in a group of normal subjects
and in patients with megaloblastic erythropoiesis due to





The control group consisted of 59 healthy subjects
who were either members of the laboratory staff or blood
donors; 2k of them were females and 35 males and their ages
ranged from 19 to 57 years.
Group II
This group comprised 23 patients with megaloblastic
folate deficiency (details of cases in Appendix CI). The
patients fell in the following aetiological sub-groups
(a) k cases with primary malabsorptive disease. The
diagnosis was established where possible by
demonstrating/
122.
demonstrating abnormal absorption of xylose, fat and
folic acid and characteristic mucosal changes in
jejunal biopsies.
(b) 5 cases with nutritional folate deficiency. The
diagnosis of this condition was based on a history of
inadequate diet in patients with a normal intestinal
absorption of folic acid and in whom no other cause
for folate deficiency could be found.
(c) 6 cases forming a mixed group of patients in whom
folate deficiency was attributed by exclusion to
coexisting diseases known to cause folate deficiency
such as lymphoproliferative disorders, drugs,
disseminated malignancy etc.
(d) 1 case associated with pregnancy.
(e) In 6 patients investigations were inadequate and
therefore the cause of folate deficiency was not
determined.
Group III:-
This group consisted of 26 patients with megaloblastic
vitamin deficiency (See Appendix C2 for details of
patients). All cases had histamine fast achlorhydria and
impaired absorption of radioactive vitamin B^. ^h®
diagnosis of Addisonian pernicious anaemia was confirmed in
16 patients either by showing correction of the abnormal
Achilling test by simultaneous exogenous intrinsic factor
administration or by demonstrating both a reduced intrinsic
secretion/
123.
secretion and total body uptake of radioactive vitamin
Group IV(Details in Appendix C3)»
This group consisted of 18 cases of severe iron
deficiency anaemia. All had a hypochromic peripheral blood
picture, low serum iron, high total iron binding capacity
and no demonstrable stainable iron in the bone marrow*
Group V:-
This group comprised 37 patients with rheumatoid
arthritis (Details of patients in Appendix Ck), This
diagnosis was based on the criteria laid down by the American
Rheumatism Association (Ropes, Bennett, Cobb, Jacox and
Jeasar 1939)*
All patients were admitted to the M.R.C. Rheumatic
Diseases Unit, Northern General Hospital, Edinburgh and a
full history including details of dietary habits, duration
of disease, drugs used in treatment taken. Patients on
drugs other than aspirin or corticosteroids were excluded
from the study. The disease activity was classified as
Grade I (inactive), Grade II (moderately active) or Grade III
(very active). The classification was based on the criteria
of Duthie et al. (1937) (Table 23) except that the degree
of anaemia was not taken into account; this was thought
advisable in a study investigating the deficiency of a
haemopoietic factor.
Effect of ACTH therapyt-



























admission and also after a remission of activity of the
disease had been induced by a 4 weeks course of ACTH
(20 I.U. intramuscularly daily during the first two weeks
followed by 10 I.U. daily during the remaining two weeks).
These five patients had generalised joint involvement and
systemic manifestations of the disease on admission and none
received folic acid during hospitalisation.
Follow-up studyt-
Seven patients, none of whom had folic acid during
the initial investigation, were recalled 3 months or more
after discharge from hospital and their plasma and erythro¬
cyte folate levels re-estimated.
METHODS.
1. Collection of bloodt-
As described in Section IV, Chapter II.
2. Plasma folate and serum vitamin estimations,
folic acid absorption and clearance studies were as described
in Chapter I.
3. Erythrocyte folate levels were those obtained using
a "control" plasma, as described in Section IV, Chapter II.
k. Haematological methods were those described by Dacie
and Lewis (1963)»
5. Serum iron and total iron binding capacity were
measured by the method of Ramsay (1957)*
6. Bone marrow slides were examined independently by two
observers/
126
observers and classified as normoblastic, early megaloblastic
or frankly megaloblastic* These observations were based
on the overall marrow picture particularly affecting the
erythroid and myeloid series* Patients whose only marrow
abnormality was the presence of a few giant metamyelocytes
were not included in the megaloblastic group*
58
7* The absorption of Co labelled Vitamin wa8
determined by the Schilling test (Schilling 195*0• The
patient fasted overnight and after an oral dose of O.^ug.
58of Co-vitamin was given a parenteral injection of
lOOOug. of non-radioactive vitamin one hour later. The
patient fasted for a further hour and collected the total
urine passed for 2h hours from the time of the oral dose*
Normal subjects excreted more than 1296 of the oral dose while
patients with pernicious anaemia excreted less than 7*5%*
8. Combined formimino-glutamic acid (FIGLU) and urocanic
acid were measured in an 8 hours collection of urine after an
oral histidine load of 15g* given to a patient who had fasted
overnight. The spectrophotometrie method of Chanarin et al.
(1962) was used. Urocanic acid and not FIGLU was used as a
standard. Urocanic acid was also estimated separately after
destroying FIGLU by autoclaving the urine at alkaline pH.
9* Jejunal biopsies were obtained using the Crosby capsule.
Specimens were initially examined under a dissecting


































10. An augmented histamine test meal was carried out
as described by Kay (1953)•
11* The sensitised sheep cell test (SSCT) for rheumatoid
factor was performed by the method of Ball (1952) modified
by the use of M.R.C* haemagglutination plates in place of
test tubes*
Investigations were carried out in the following
orderi-
Collection of blood, bone marrow puncture, FIGLU test,
folic acid clearance and finally folic acid absorption*
RESULTS.
Plasma folate levels;-
The mean and range of the plasma folate content in
each group is shown in Table 2*K
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The erythrocyte folate levels
Figure 18 shows the erythrocyte folate values
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All oasea had subnormal erythrocyte folate levels
(Figure 18). In 83% (19 cases) the levels were less
than 60eug/ml. packed cells. There Is poor correlation
between the degree of anaemia and erythrocyte folate
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Megaloblastic vitamin B12 deficiency.






























■ I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 r i
3 4 5 6 7 6 9 10 11 12 13 14 15 16 17 18 19 20
Plasma folate ( mug /ml.)
Lower normal limit for Erythrocyte folate
Lower normal limit for Plasma folate
The relationship between plasma and erythrocyte
folate content in patients with megaloblastic anaemia
due to vitamin deficiency, r » 0.62 P < 0.001.
132.
(ii) Vitamin B deficient:
Figure 18 shows that in 10 cases (38%) the
erythrocyte folate levels are subnormal.
However, only h- cases had levels comparable
to those encountered in the majority of the
folate deficient subjects i.e. less than
60mug/ml. of packed cells.
Figure 20 relates the plasma and erythro¬
cyte folate levels and shows a good correlation
between the two r = 0.62 P<.001.
There is poor correlation between the
haemoglobin concentration (g. per cent) and
the erythrocyte folate levels (mug/ml. packed
cells) (Figure 21) r = 0.36 P< 0.1 ^0.05.
133 •
Figure 21.
Megaloblastic Vitamin Bi? deficiency.
300 -|




100 H # * •
50-
-I 1 1 1 1
3 6 9 12 15
haemoglobin g.V.
Haemoglobin concentration (g.JO related to erythrocyte
folate content in megaloblastic vitamin B.p deficiency,
r » 0.36 P < O.l 7 0.05. "
m.
II. Iron Deficiency Anaemia.
The highest erythrocyte folate levels (mug/ml.
packed cells) were observed in this group (figure 18).
The nean 329 SD ♦, 126 is significantly higher than that
of the control group P < .001.
The plasma folate content (mug/ml.) shows a good
correlation with the erythrocyte folate level r a 0.7
P < 0.001 (Figure 22).
FIGURE 22.
Iron deficiency anaemia.
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Lower normal limit for Erythrocyte folate
Lower normal limit for Plasma folate
r » 0.7 P < 0.001.
135.
FIGURE 23.
The Mean Corpuscular Folate Content.
Normal Megaloblastic Megaloblastic Iron































x - Megaloblastic subjects with subnormal erythrocyte
folate levels when calculated as (mug/ml. packed cells),
o - Iron deficient patients with erythrocyte folate levels
( mug/ml. packed cells) above the upper limit of normal.
The closed circles represent subjects in whom both
erythrocyte folate (mug/ml, packed cello) and MCF
values were either normal or subnormal.
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THE MEAN CORPUSCULAR FOLATE CONTENT (HCF).
The mean folate content per red cell was calculated as
follows
MCF (uug) = Folate uug/ml. of packed cells.
Number of erythrocytee/ml, of packed cells.
The number of erythrocytes in one ml. of packed cells
was calculated as follows
BBC/cumm of blood x 100 x 10^
packed cell volume.
The MCF in 20 normal subjects varied from 1.16 to
—8
2.35 x 10 uug. The index was also determined in 13 folate
deficient subjects, 17 vitamin deficient subjects and 8
cases with iron deficiency anaemia.
All MCF values were multiplied x 10 ^ and compared in
Figure 23.
6 megaloblastic cases (5 vitamin deficient and 1
folate deficient) who had subnormal erythrocyte folate levels
(mug/ml. packed cells) (Figure 18) were found to have normal
MCF values. Conversely 3 iron deficient patients whose erythro¬
cyte folate levels (mug/ml. packed cells) were above the upper
limit of normal had MCF values within the normal range.
Calculation of the erythrocyte folate content in mug/ml. of
packed cells does not take into account the mean corpuscular
volume and gives no information therefore on the folate content
per cell. The MCF on the other hand stands for the absolute


































































The open circles shown in this and subsequent
figures stand for patiente with an early




These are compared in Figure 24 with the levels found
for normals and megaloblastic folate deficient subjects. 24
cases (65%) ih the rheumatoid arthritis group had subnormal
levels i.e. less than 2.6mug/ml. In 17 of these the plasma
folate levels fell within the range found for the megaloblastic
folate deficient patients I.e. 2.0mug/ml. or less; only five
cases in the latter group showed megaloblastic changes in the
bone marrow, and in all of these the abnormality was classified
as early.
Erythrocyte folate levels
Figure 18 shows that 14 cases (38%) have subnormal
levels ranging between 55 and 120mug/ml. packed cells.
(a) Related to plasma folate content
A good correlation is shown between the plasma and
erythrocyte folate levels r = 0.75 P-C.001 (Figure 25)» The
figure also shows that whereas all 14 cases with subnormal
erythrocyte folate levels have reduced plasma folate values,
there are 10 cases in whom a subnormal plasma folate level is
associated with a normal erythrocyte level.
(b) Related to haemoglobin concentration (g.%):-
No relationship was shown in rheumatoid arthritis
between the haemoglobin concentration (g.%) and the erythro¬
cyte folate content (mug/ml. of packed cells).
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Plasma folate mug /ml
o Megaloblastic cases
— Lower normal limit for Erythrocyte folate content.
— Lower normal limit for Plasma folate content.
—« Upper limit of plasma folate in megaloblastic folate deficiency.
Plasma folata content related to erythrocyte
folate content in rheumatoid arthritis.
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The bone marrow was normoblastic in 29 cases (80%).
The remaining 8 cases showed an early megaloblastic change.
The haematological data of these cases are shown in Table 25.
Folic Acid Clearance
This test was performed on 8 of the total cases.
The results are shown on Figure 27. Table 26 gives the
haematological data on these patients. Erythropoeisis was
normoblastic in all patients studied. Cases 3, 30 and 5
who showed a very rapid clearance of folic acid also had
subnormal plasma and erythrocyte folate levels and two of
them (30 and 5) excreted high quantities of FIGLU and urocanic
acid in the urine. A rapid clearance (especially at 15 and
30 minutes) was also obtained in Case k in whom the only
abnormality was excessive excretion of histidine metabolites
and Case 20 who had a subnormal plasma but normal erythrocyte
folate level.
Histidine Metabolites in Rheumatoid Arthritis.
The range for FIGLU excretion in 13 normal subjects
studied was 0-20 mg/8 hours, and for urocanic acid 0 - 4mg/8
hours. The upper limit of normal for combined FIGLU and
urocanic acid excretion or FIGLU alone is tauten as 25mg/8 hours
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FIGLP Excretion in Rheumatoid Arthritis*
(i) Relation to plasma folatei-
23 of 35 cases investigated (64#.) excreted abnormal
quantities of FIGLU in the urine (more than 25rag/8 hrs).
8 of these had normal plasma folate levels (more than
2.6mug/ral). Conversely FIGLP excretion was normal in 8
cases with subnormal plasma folate levels (Figure 28).
FIGPRE 28.
Relationship between FIGLU excretion and Plasma
folate levels in Rheumatoid Arthritis.
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Upper limit of normal for FIGLU.




(ii) Relation to erythrocyte folate levelsi-
Figure 29 shows that 13 of those who excreted abnormal
quantities of FIGLU had normal erythrocyte folate levels
and that the highest quantities excreted fell in this
group. Also three cases with subnormal erythrocyte folate
levels excreted normal quantities of FIGLU.
FIGURE 29.
Rheumatoid Arthritis
FIGLU excretion related to Erythrocyte folate levels.
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Erythrocyte folate mug /ml packed cells
o Megaloblastic
Erythrocyte folate lower normal limit
-x—x—x-FIGLU upper normal limit
Ik?.
Urocanic Acid Excretion:
23 cases (66%) excreted urocanic acid in excess of
5mg/8 hours (Figure 30). Excessively high levels (more than
150mg/8 hours) were obtained in k cases. Two of these had a
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148.
FIGURE 31.
Relation of Plasma and Erythroyte folate content to
disease activity in rheumatoid arthritis.
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Relation of various parameters to activity and duration of
of disease in rheumatoid arthritis.
1. Disease Activity:-
(a) The erythrocyte and plasma folate content are related to
disease activity in Figure 31* There appears to be no
correlation of either measurement with disease activity.
Thus of the 22 cases listed as Grade II, 50% had subnormal
erythrocyte folate levels and 77% subnormal plasma folate
levels. The corresponding percentages in Grade III are
10 and 40 respectively.
(b) The relation of total FIGLU and urocanic acid to disease
activity is shown in Figure 32. The number of patients
with Grade I disease activity is too small to allow
statistical comparison with the other groups. All
patients with Grade III disease activity excreted abnormal
quantities of histidine metabolites in the urine as
compared to 80% (18 cases) of those with Grade II. The
much smaller number of patients in the former Grade,
however, makes the significance of such a finding
doubtful.
(c) The effect of ACTH therapy on the plasma and erythrocyte
folate values t-
The haeraatological indices and the folate values assessed
in five subjects before and after a remission of the
disease activity had been induced by ACTH therapy are
shown in Table 27.
150.
FIGURE 32.
Total FIGLU and Urocanic Acid related to disease
activity in rheumatoid arthritis.










































































30 A 9.6 70 Ill 1.4 153
B 14.6 10 I 1.3 125
27 A 8.2 87 III 2.5 163
B 11.4 25 I 2.2 155
33 A 8.6 48 II 2.7 259
B 13.5 k I 2.3 245
35 A 10.7 74 III 3.9 135
B 15.4 6 I 4.0 177
34 A 9.0 77 III 4.3 30k
B 10.2 18 I 4.5 286
The "initial" and post ACTH data on the five
subjects studied.
The differences between the initial and post ACTH
plasma and erythrocyte folate values were not significant.
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2, Relation of erythrocyte folate level and combined FIGLU
and urocanic acid excretion to duration of disease*
(i) Erythrocyte folate levels
Figure 33 ahows that there is no relationship between
chronicity of the disease and the erythrocyte folate
content and that there is considerable overlap between
the four groups.
FIGURE 33.
Erythrocyte folate content related to duration of
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153.
(ii) FIGLU and urocnnic acid:-
Giailarly no correlation wan shown between this parameter
and duration of disease (Figure 3*0. Four of the cases
who had the disease for more than 10 years (13* 1^* 25
and 30 years respectively) excreted normal quantities
while two cases who had it for 3 and ^ months respectively
excreted 110 and 680mg/8 hrs.
FIGURE 3*t.
Relation of combined FIGLU and Urocanic acid to duration
of disease in Rheumotoid Arthritis.
N* of
Cases
6 U 9 6
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-x—x—x-Upper limit of normal for FIGLU and Urocanic acid excretion.
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FOLLOW-UP 5TUDY.
The plasma and erythrocyte folate values were
determined for 7 patients with rheumatoid arthritis three
months after discharge from hospital and compared in Table 28
with those which were obtained at the beginning of the study.
None of these patients had received any folic acid.
TABLE (28).
Initial and follow-up plasma and erythrocyte folate levels.
Plasma folate Erythrocyte folate
mug/ml. mug/ml. packed cells.
Initial F. up Initial F. up
1 2.3 1.9 225 233
2 6.1 4.7 251 185
3 2.4 1.5 290 205
4 1.9 2.0 109 160
5 2.3 2.3 189 144
6 3.7 2.7 282 222
7 5.0 3.5 199 204
t = d _ 1.700 (df,6) 1.465 (df,6)
^var)dn
<0.1 <0.2
* See Appendix B1•
The follow up plasma and erythrocyte folate values of
cases 2, 3 and 6 are lower than the initial ones. Statistically
however, the difference in either parameter is not significant
for the number of patients studied.
155.
The excretion of histidine metabolites in
rheumatoid arthritis patients with normal
erythropoiesis and folate values*
Twelve patients who had normal plasma and erythrocyte
folate values and in whom erythropoiesis was normoblastic
were found among the 37 cases of rheumatoid arthritis studied.
10 of these excreted abnormal quantities of either FIGLU or
urocanie acid or both in the urine (Table 29). Excessive
amounts (more than 100mg/8 hours) of combined histidine
metabolites were obtained in k cases with Grade III and 3
eases with Grade II disease activity respectively. Case 10
who was only mildly affected excreted normal amounts. Five
of a total of 10 cases with generalised severe disease
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TABLE(2Q).
Durationof disease,yrs. 1 2 9 7/12 1 18/12 1 6/12 22 13 1
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The effect of plasga from rheumatoid arthritis
patients on the folate content of normal plasma.
METHOD.
Fresh plasms samples were obtained as described
previously from a normal subject and three rheumatoid arthritis
patients. Each patient's plasma was combined with differing
quantities of normal plasma to give mixtures containing 20%,
50% and 80% respectively of the former. 10mg. of dry
asoorbic acid per ml. was added to all plasma mixtures as well
ae to the original k samples. All samples were incubated
for 30 minutes at 37°C. and then extracted and assayed as
described.
RESULTS.
The folate values (mug/ml.) obtained for the nine
combined plasma samples are shown in Table 30. They are
compared with the "expected" values which were calculated
from the folate oontents and relative percentages of normal
and patient plasmas in the various mixtures. The assayed
and expected values are similar even in samples containing
80% of patient plasma^ which indicates that plasma from
patients with rheumatoid arthritis has no inhibitory effect
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DISCUSSION.
The present study shows and confirms previous reports
by Hansen and Weinfield (1962), Cooper and Lowenstein (196*0,
Mollin and Hoffbrand (1965), Hoffbrand et al. (1966,a) that
reduced erythrocyte folate levels are found in megaloblastic
anaemia due to either folate or vitamin B^2 deficiency. The
lowest levels were observed in the folate deficient group
where 85% of patients had values less than 60mug/ml. packed
cells (lower normal limit is 135aug/ml. packed cells). In
contrast only 15% of the vitamin B^2 deficient patients had
such low values.
As reported previously by Cooper and Lowenstein
(196*0 and Hoffbrand et al.- (1966,a) the present study also
shows that the erythrocyte folate content in vitamin B^2
deficiency is relatively low when compared to the correspond¬
ing plasma folate value. Thus the mean erythrocyte/plasma
folate ratio in normal controls is 42:1 as compared to 18:1
in Vitamin B12 deficiency. Further, 9 patients with normal
plasma folate values had subnormal erythrocyte folate levels.
Cooper et al. (1964) suggested that this altered serum/
erythrocyte folate relationship may indicate interference with
the transport of folate into the maturing red cell precursor.
Although the disordered folate metabolism known to occur in
vitamin B^2 deficiency may be in the form suggested by Cooper
et al., the demonstration of a good correlation between plasma
and erythrocyte folate levels in this condition also noted by
these/
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these workers, suggests that the folate content of nature
erythrocytes in vitamin deficiency may in addition depend
on the amount of folate available for the developing red cell*
There is no doubt that reduced erythrocyte folate values nay
occur in vitamin deficient patients whose plasma folate
levels are well within the normal range (Figure 20), which
indicates a predominant metabolic block to folate utilisation*
On the other hand the fact that all k cases who had
erythrocyte folate values less than 60mug/ml* also had low
normal or marginal plasma folate levels indicates that the
occurrence of such erythrocyte folate values in vitamin B^2
deficiency may result from an associated folate deficiency*
This is especially so since in view of the tendency for the
serum folate activity to accumulate in vitamin B^2 deficiency
low normal or marginal serum levels may indicate a significant
degree of folate deficiency (Herbert et al. 1962b*)•
The mean corpuscular folate content (MCF).
The erythrocyte folate content when expressed as
mug/ml. packed cells is a measure of folate concentration
per unit volume of cells* Due to variation of the mean
corpuscular volume in different types of anaemia it does
not provide accurate information on the absolute folate content
per cell. Such an index, the mean corpuscular folate content
(MCF), was calculated for normals, patients with megaloblastic
anaemia and for iron deficient subjects in order to see whether
the/
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the intracellular folate is the same or different in these
conditions* Normal (MCF) values were obtained in 6 megalo¬
blastic cases (5 deficient and 1 folate deficient) who had
subnormal erythrocyte folate levels (in mug/ml* packed cells)
showing that although in some cases the macrocytes of vitamin
B^2 deficiency and to a lesser extent those of folate deficiency,
have a low intracellular folate concentration, they do in fact
have a normal folate content* A true intracellular
folate deficiency was shown to exist, however, in all but one
of the folate deficient group and in A out of the 17 vitamin
patiMt*.
Arguing on the same lines the abnormally high erythro¬
cyte folate values observed for some of the iron deficient
subjects may be explained by the presence per unit volume of
a larger number of cells than normal providing that the
microcytes of iron deficiency have normal MCF values. This
was the case in 3 subjects all of whom had erythrocyte folate
values above the upper normal limit in Figure 18 and normal
MCF values in Figure 23* In k subjects, however, the MCF
values were higher than normal. The reticulocyte count in
this group varies from 1-3% and none of the patients had a
significant blood loss at the time of investigation (Appendix
C3)» It is tempting to postulate as an explanation for this
that the developing iron deficient red cell precursor receives
its normal complement of folate and that by producing, during
the different stages of maturation, a cell with a small
nucleus/
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nucleus and cytoplasmic mass, it utilises less folate than
normal thus giving rise to a mature erythrocyte with an
increased intracellular folate content. The lack of either
iron or folate interferes with proper utilisation of the
other and in combined deficiency treatment with the one
haeraopoietic agent precipitates the full blown deficiency
picture of the other. Further, the accumulation of folate
in the iron deficient cell may have the same significance as
the occurrence of sideroblasts and siderocytes in uncomplicated
megaloblastic erythropoiesis. Finally it is of interest to
note that Cooper and Lowenstein (196*0 noted an unexplained
reduction in the serum folate for the corresponding erythrocyte
folate (mug/ml. packed cells) in iron deficiency anaemia.
163.
THE FOLATE STATPS IS RHEUMATOID ARTHRITIS.
The finding of subnormal plasma folate levels in the
majority of the rheumatoid arthritis patients investigated in
the present study is in agreement with previous reports (Gouch
et al. 1964, Cellar et al. 1966). The serum folate is a
sensitive index of folate deficiency and had been shown to fall
to deficiency levels within 3 weeks from the consumption of a
folate deficient diet while a subnormal erythrocyte folate
content and megaloblastic erythropoiesis took 4 and 4£ months
respectively to develop (Herbert 1962, 1965)* Clinical
studies have also shown that patients may continue for long
periods with subnormal serum folate levels without manifest
evidence of tissue depletion (Hellraan et al. 1964) or easily
recognisable morphological bone marrow changes (Mollin and
Hoffbrand 1965)# In a series of non-anaemic patients with
subnormal serum folate levels Hoffbrand et al. (1966a) found a
good correlation between the serum and erythrocyte folate
levels; further serum folate levels in the unequivocal
deficiency range (less than 3.0mug/ml. in their series) were
almost invariably associated with subnormal erythrocyte folate
levels with variable degrees of megaloblastic change in the
bone marrow.
Both experimental and clinical studies would appear
to indicate that a low serum folate may precede by a long
time a reduction in the folate content of haemopoietie tissue
as indicated by a reduced erythrocyte folate level and abnormal
bone/
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bone marrow morphology. The significance of a low serum folate
level is beat therefore assessed by estimating the erythrocyte
folate content and looking for haematological changes.
The plasma folate level in rheumatoid arthritis
correlated well with the erythrocyte content but the mean
erythrocyte/plasaa folate ratio in this condition (72il) is
much higher than in controls (42j1) indicating a greater than
normal but proportionate reduction in the plasma folate
activity to that of erythrocytes in rheumatoid arthritis.
Further the erythrocyte folate levels were normal in 10
cases with subnormal plasma levels ranging from 1.5 - 2.3
mug/ml. and in 4 of whom the levels were less than 2.0mug/ml.
i.e. within the range found for megaloblastic folate deficiency.
There was no significant drop in either parameter in 7 patients
reinvestigated 3 months after the completion of the initial
study. It is obvious therefore that rheumatoid arthritis
patients may continue having reduced plasma folate activity
in the face of slight or no deficiency in the folate content
of haemopoietic tissue. This reduction in the plasma folate
activity is genuine and inhibitors to L. casei growth have
been excluded in this and other studies (Cowan et al. 1966).
In the light of the previously referred to experimental and
clinical studies, this disturbed plasma/erythrocyte folate
ratiA may be partly explained by a "subclinical" or
developing folate deficiency. The occurrence, however, of
normal erythrocyte folate levels in some patients with
unequivocally/
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unequivocally deficient plasma values may indicate that the
plasma folate activity in rheumatoid arthritis does not have
the same significance as it does in other folate deficient
states.
There is also a striking paucity of megaloblastic
change in patients who should theoretically have a significant
degree of folate deficiency as manifested by both a subnormal
plasma and erythrocyte folate level. Thus, of l*f such cases,
15 of whom had plasma folate values of 2.0mug/ml. or less,
only b showed bone marrow changes suggestive of megalo-
biastosis and in all of these including one case (No. 33
Appendix Cb) % with plasma and erythrocyte folate levels of
1.5 and 55mug/ml. respectively, the abnormality was classified
as early. Erythropoifesis and myelopoissis were entirely
normal in the remaining 9 cases. Three of these cases
(No. 5t 30 and 3) in addition to being deficient in both
plasma and erythrocyte folate values showed a fast clearance
of injected folic acid and excreted abnormal quantities of
histidine metabolites in the urine. In the eeries of
rheumatoid arthritis patients reported by Gough et al« (1964-)
mild to moderate megaloblastic changes were found in only 6
out of 15 patients with serum folate levels in the unequivocal
deficiency range. Comparison with the other folate deficient
states in this study and with the series reported by Hoffbrand
et al. (1966,a) shows that megaloblastic change.'' In rheumatoid
arthritis is by far less frequent and when present less
severe/
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sever* than would be expected from the degree of folate
deficiency. Such a comparison has its limitations because
whereas folate deficiency is the main cause of anaemia In
the 23 megaloblastic cases included in this study (Appendix CI)
and of the haematological abnormalities in those reported by
Hoffbrand et al. (I966,a), the cause of anaemia in rheumatoid
arthritis is not known and the aetiological significance of
folate deficiency in its pathogenesis uncertain. A co¬
existent impairment of haemoglobin synthesis as occurs in iron
deficiency or haemoglobinopathiee may mask the overt megalo¬
blastic changes of folate deficiency (Herbert 1965). In the
same way the hypochromic element of rheumatoid arthritis may
be responsible for the discrepancy between the morphological
bone marrow changes and the results of other test6 of folate
deficiency.
Histidine Metabolites.
The compound formiminoglutamic acid (FIGLU) arises
from theih ^vivo degradation of histidine and is normally
converted to glutamic acid by donating its formimino group
(CHsNH) to tetr&hydropteroylglutamic acid in a reaction
involving the enzyme FIGLU transferase. A lack of the
folate coenzyme - as occurs in folate deficiency - causes
FIGLU to accumulate in the urine (Broquist and Lubby 1959).
The abnormality is easily demonstrated by loading the metabolic
pathway with histidine (Lubby et al. 1959)* A high FIGLU
excretion/
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excretion is a constant finding in megaloblastic anaemia
requiring treatment with folic acid, an exception being the
anaemia of pregnancy where due to abnormality in histidine
metabolism the test is unreliable (Chanarin et al. 1963)* A
disadvantage of the test is its lack of specificity in that
a positive result may occur in vitamin deficiency
(Zaluoky and Herbert 1961, Kohn et al. 1961, Kershaw and
Girdwood 1964) and in conditions with neither folate nor B, _12
deficiency e.g. liver disease (Carter et al. 1961) and
malignancy (Kershaw and Girdwood 1964, Watson-Williams and
Israels 1966)*
Another histidine metabolite and a precursor of FIGLtf
is urocanic acid. Urocanic acid may be the major or only
histidine metabolite in the urine of folate deficient subjects
(Chanarin and Bennett 1962, Chanarin 1963$ Hohmed and
Roberts 1966). Abnormal urocanic acid excretion had also
been reported in patients with status asthmaticus (Kerr 1963)$
Kwashiorkor (Whitehead et al. 1961) and thyrotoxicosis
(Mohmed and Roberts 1965)*
A relationship has been shown in folate deficiency
between FIGLU excretion and the serum folate level. Thus
in 70 patients suffering from intestinal malabsorption, Crohn's
disease or who had undergone partial gastrectomy reported by
Hollin and Hoffbrand (1965) & positive FIGLU test was shown
in those with serum folate levels in the unequivocal
deficiency range and a negative result in all of those with
normal/
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normal serum values. Similarly all 26 patients with
primary malabsorptive disease and subnormal folate values
reported by Kershaw and Girdwood (196^) excreted large
quantities of FIGLU in the urine.
The urinary excretion of histidine metabolites in
rheumatoid arthritis follows a different pattern from that
described for otner folate deficient states. There was no
clear cut relationship for example between the plasma folate
activity and FIGLU excretion. Thus, while in some patients
with subnormal folate levels FIGLU excretion was normal, 8
out of 12 patients with normal plasma folate values excreted
large quantities of FIGLU in the urine (Figure 28). An
even greater dissociation was observed between FIGLU excretion
and erythrocyte folate content where abnormal FIGLU excretion:,
sometimes excessive, occurred in a large group of patients
with normal erythrocyte folate levels. The latter finding
is at variance with the findings of Hoffbrand et al. (1966^
who observed a correlation between the two parameters in the
majority of patients with folate deficiency due to causes
other than rheumatoid arthritis. Further, abnormal excretion
of combined FIGLU and urocanic acid (with^a variable
preponderance of either) was observed in 10 out of 12 patients
who had normal plasma and erythrocyte folate values and in
all of whom erythropoeisis was normoblastic (Table 29)*
One of these patients (Case 21) who excreted the highest
amount/
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amount of histidine metabolites (6l6mg/8 hrs.) in the whole
group of patients investigated, showed in addition a normal
clearance of injected folic acid. All 10 patients had
generalised joint and systemic manifestations of the disease
(Grades II and III severity).
The excretion of abnormal quantities of histidine
metabolites by rheumatoid arthritis patients in the face of
a normal folate status is difficult to explain. A similar
situation was observed in malignant disease by Watson-Williams
and Israels (i960) where large quantities of FIGLG were
excreted by patients who had normal serum folate values and
normoblastic bone marrows.
The excretion of histidine metabolites is not related
to the duration of disease in rheumatoid arthritis. The
proper evaluation of its relationship to disease activity is
hampered by the presence of only k patients with Grade I,
as compared to 32 patients with Grades II and III disease
severity (Figure 32). However, in two of the mildly affected
patientB (Grade I) the urinary excretion of histidine
Metabolites was normal and was only marginally raised in a
third patient. The fourth patient who eliminated a total of
83mg/8 hrs. showed also an early megaloblastic change in the
bone marrow (Case 25, Table 25)* In contrast all patients
with Grade III disease activity and 18 out of 22 oases with
Grade II excreted abnormal quantities of combined FIGLU and
urocanic/
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urocanic acid. It is possible therefore that the excretion
of abnormal quantities of histidine metabolites is commoner
in the more severely affected patients#
Moat observers would agree that a positive FIGLU
test indicates disordered folate metabolism due to either
lack or interference with function of the folate coenzyme
or of FIGLU transferase.
Folate deficiency may therefore be responsible for
the excretion of large quantities of FIGLU in the urine by
those rheumatoid arthritis patients who had other criteria
of the deficiency e.g. reduced folate levels or morphological
bone marrow changes suggestive of megaloblastic erythropodesis.
The occurrence of a positive FIGLU test on the other hand in
patients who have a normal folate status may indicate a dys¬
function of FIGLU transferase possibly related to disease
activity.
Since folate compounds are not directly involved
in the breakdown of urocanic acid, the mechanism whereby
folate deficiency causes a high excretion of this metabolite
is obscure. Allan and Whitehead (19^5) produced evidence
that the excessive excretion of urocanic acid observed in
children with protein malnutrition is caused by the hypo-
proteinaemia and not folic acid deficiency. They suggested
that the hypoproteinaeraia may depress urocanase synthesis.
Similarly Hoffbrand et al. (1966,b) found that patients who
had undergone partial gastrectomy and had subsequently
developed/
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developed low serum albumin levels excreted large quantities
of urocanic acid and that this was reversed to normal by
intravenous albumin infusion. Seduced serum albumin, levels
are frequent in patients with rheumatoid arthritis (Gutman
19^). The degree of reduction correlates with the clinical
activity of the disease and degree of anaemia (Engstedt et al.
1966). It is possible on purely speculative grounds that
urocanic acid excretion in rheumatoid arthritis is linked
with the plasma protein disturbance frequently seen in this
disease.
Of interest is the finding by Edozien and Obasi
(I965) of a correlation between the excretion of urocanic
acid after a histidine load and of xanthurenic acid after a
typtophan load in patients with protein malnutrition
(kwashiorkor). They argued that since the excretion of
xanthurenic acid after tryptophan loading is a reliable test
of pyridoxins deficiency (Greenberg et al. 19^9) and since
the enzyme urocanase has pyridoxal requirements (Gupta and
Kobinson 1961), the excretion of abnormal quantities of
urocanic acid after a histidine load in these patients
reflected pyridoxine deficiency. They suggested that uro¬
canic acid excretion after a histidine dose is a sensitive
index of pyridoxine deficiency.
Abnormalities of tryptophan metabolism in patients
with rheumatoid arthritis have been reported (Bett 1962,a
and b) and a relative deficiency of pyridoxine suggested as
causing/
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causing these (McKueick et al. 1964, Bett 1966).
This provides another possible explanation for the
raised excretion of urocanic acid in rheumatoid arthritis
if one accepts the postulate of these workers.
Aatiological factorsi-
Gough et &1. (1964) found that the dietary intake
of folic acid in patients with rheumatoid arthritis did not
differ significantly from that of controls and that ths
intestinal absorption of the vitamin was normal in the 6
megaloblastic cases found in the group.
Histories of adequate dietary intake were obtained
in all oases in the present series with the exception of two
(Ho. 33 and 13* Appendix C4)j the intestinal absorption of
folio acid was also shown to be normal in the 16 cases
investigated. further, preliminary results have also shown
that the urinary loss of folic acid in rheumatoid arthritis
is not different from that in controls.
Increased utilisation of folic acid by the cellular
proliferation in the Joints in rheumatoid arthritis was
suggested by (touch st al. (1964). Utilisation of folate
by the autoimmune process and the hyperactive reticulo¬
endothelial system may in addition increase the demands for
the vitamin. This concept of increased utilisation is very
possible but difficult to prove.
Neither the incidence nor the degree of folate
deficiency/
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deficiency could be related to the duration or severity of
the disease. The plasma and erythrocyte folate levels
remained unchanged in 5 patients in whom a remission of
disease activity and a significant rise in haemoglobin
concentration were produced by ACTH therapy.
The plasma folate releasing facton-
Tbe significance, in relation to folate deficiency,
of the reduced folate releasing ability of plasma in
rheumatoid arthritis shown in flection IV of Chapter II is
uncertain, Grzesiukowicz et al, (1966) demonstrated a
reduced "plasma factor activity" in megaloblastic anaemia
of pregnancy and suggested that this may lead to less
utilisation of the "folate activity precursor" from erythro¬
cytes thus reducing the available folate in the circulation
and contributing to the aetiology of folate deficiency.
There are two main criticisms of this concept
1. The imvitro conditions under which optimal folate
release occurs e«g, pH, are far removed from those prevailing
in the human body. The conclusion therefore that the
results of such experiments represent the ih vivo inter¬
relationship between the folate precursor and the releasing
factor is not justifiable,
2. The concept that the folate content of the erythro¬
cyte is eventually re-utilised in the body is acceptable.
However, since the destruction of red cells occurs normally
in the reticuloendothelial system, it is more likely that
the/
17^.
the folate precursors are removed and stored there in a
way similar to haemoglobin iron and that the polyglutaraate
forms broken to sonoglutamates by nconjuga8esn in the
reticuloendothelial system* Herbert (19^2) had shown that




1. In agreement with previous reports, reduced
erythrocyte folate values were found in megaloblastic
anaemia due to either folate or vitamin B^2 deficiency.
2. The mean corpuscular folate content (MCF) was
determined in normal controls, patients with megalo¬
blastic anaemia and in patients with iron deficiency
anaemia and its significance evaluated in the various
groups,
3. The occurrence of folate deficiency in rheumatoid
arthritis was confirmed. Evaluation of the various
findings showed that:-
(a) Subnormal plasma folate values are common in
rheumatoid arthritis, occurring in Zk out of 37 patients
investigated* The erythrocyte folate levels were
reduced in only 14- of these patients indicating that a
reduced plasma folate activity in this disease is not
necessarily associated with a significant degree of
folate depletion.
(b) Both the incidence and severity of the megalo¬
blastic change in the folate deficient rheumatoid arthritis
patients are less than would be expected from the degree
of the folate deficiency.
(c) Histidine metabolism is abnormal in rheumatoid
arthritis and in many cases unrelated to the folate
status. Possible causes for this were discussed.
(d) /
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(d) The possible causes of folate deficiency and
the significance of the reduced plasma factor activity






An Elgastat portable dioniser type B. 102 was used.
Deionised wster wae used for rinsing glassware, preparation
of media, buffers, standard folic acid solutions, haemolysatee,
ascorbic acid solutions, dilution of extracts prior to assay




(i) Glassware used for folate estimation:
(a) Pipettes were soaked in a detergent "pyroneg" for
at least 12 hours, transferred to an automatic washer
overnight, rinsed with deionised water and. dried in a
hot air oven.
(b) Universal containers, test tubes, flasks, measuring
cylinders etc. -
Universal containers and test tubes were first
brushed thoroughly with hot Pyroneg solution, then
together with the rest of glassware filled with Pyroneg
for six hours before they were washed well in running
tap water, rinsed with deionised water and dried in a
hot air oven.
(c) Aluminium caps were soaked in a weak Pyroneg
solution/
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solution, washed in running tan we^er first then
deionised water and finally dried in a hot air oven,
(ii) glassware used for vitar,!n B estimation:
This was always acid cleaned. The acid solution was
prepared as follows
Potassium dichroraate 5 150 g.
Cone, sulphuric acid t 500 ml.
Distilled water j 1350 ml.
Final volume : 2000 ml.
The glassware was first filled with the acid solution
and left overnight, then washed in running tap water,




DIFCO microinnoculum broth was rehydrated by dissolving
37g. in 1000 ml. of deionieed water. 8 ml. aliquote of the
medium were dispensed into 3'x 5/8" test tubes which were
plugged with cotton wool, sterilised at 15 p.s.i. for 10
minutes and stored at k°C, until used.
(b) S. faecalis:-
To *f00 ml. of DIFCO folic acid assay medium prepared
by dissolving 7.5g./100ml. of water were added 3»2ug. of
folic acid (8 ml. of 1/100 dilution of the stock folic acid
solution). After boiling for 2-3 minutes the medium was
dispensed/
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0.1*# Tryptone t ^75 nl«
DIFCO Euglena B medium : 52^ "
Vitamin solution (2raug/ral.) 1 "
Total volume : 1000 "
10 ml. aliquots were dispensed into universal containers,
sterilised by steaming at 100°C. for 15 minutes and stored
at *f°C.
IV.
PREPARATION OF PHOSPHATE BUFFER.
Stock Solutions:- The reagents used were "Analar" grade.
Solution A.
0.2 M sodium dihydrogen orthophosphate (Na H^ PO^
2H^0 ) prepared by dissolving 52.2g. in a litre of deionised
water.
Solution B.
0,2 M Di~sodiura hydrogen orthophosphate (Na^H PO^
121^0) prepared by dissolving 71»7g» in a litre of deionised
water.
The stock solutions were kept at room temperature,
and 0,1 M phosphate buffer pH 6.1 - 6.2 was prepared when
required/
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required by adding 85 ml. of solution A. to 15 ml. of
solution B, and diluting with an equal volume of water.
When such a buffer contained 200mg.% ascorbic acid the pH
varied from 6.0 - 6.1.
V.
Quantities of HC1 and ftaOH required for obtaining
haeaolysates at different pH values.
The number of drops of HC1 or HaOH added by a
Pasteur pipette (15 drops/ml.) to 9 ml. of water or ascorbic
acid solution in order to obtain different haemolysate pH
values (blood dilution 1/10), are detailed in the table





































25mg.% ascorbic acid solution. lQOmg.% ascorbic acid solution.
Expected pfi
range.








No. of drops of
HC1 or NaOH.
2.8 - 3.0 P' ■: 7 5- HC1
|p;, ' '
2.3 - 2.4 8 N HC1
T






m\v 6 * 2*5 ~ 2.0 7 " 2.4 - 2.5 8 rt




























VJ» . M 1 vn . ■r " +l| HC1 4.3 - 4.5 1 NHC1+ § HC11 £
if HCl+lf HC1 5.5 - 6.0 1 JtHCl 4.6 - 5.0 1 N. HC1t
' 1 f HCI* 6.0 - 6.5 1 | HC1 5.1 - 5.5 X | HC1
None 6.7 " 6.9 None 5.6 - 5.8 None
l| NaOHw &
i.-5
7.0 - 7.5 if NaOH 6.0 - 6.5 if NaOH
■| 1 » HaOH
i
7.5 - 8.0 1 It NaOH
1

















NaOH was added prior to addition of blood and the quantities





1, Arithmetic Mean (x).
a
Where $x!' is the sura and Hn" the number of sample results.
2. The Standard Deviation (SD).
SD at I/Variance « \J
rt2
- JL (i* - <** ^X
n-1
Where
n » number of results.
£2x » the sum of the squares of individual results,
(^x) = the square of the sum cf total results.
3. The Significance Tests.
A. The Student's "t" test.
This test was used to compare sets of results
conforming; to the following conditions
(i) Sample results must be independent.
(ii) The two population variances are normally distributed.
(iii) The two population variances are equal. This is






Where Sa is the variance and n the number of the
a
first set of results and S, , n. the variance and number ofb' b
the second set of results respectively.
For the "t" test to be applicable, the two variances
must not be significantly different as judged by looking at
the calculated "F" values in 3% MF" tables with degrees of
freedom of » (n -1) and = (n.-l).
a b
Formula for the **t" testi-
mm mm
Xa ~ xb "degrees of freedom"
V ® 1 - 1 L 1 Jl ■ ■11
_2 _2 = (n + n. — 2)




(i) xft, x^ are the means and na, nfc the number of the two
sample results compared respectively,
2
(ii) S is the pooled variance of the two sample results,
P
calculated as follows
g' = (n ~ 1) x i>2 + (n, - 1) x S2
p a a b b
n + n, - 2
a b
When the sample results are not independent e.g.
comparison between the initial and follow up folate values
of the same patients, the rt" test cannot be used. Instead
the following formula is applicable
t * 5 *
variance (d)
"t" has 'degrees of freedom' of n - 1.




n ■ number of differences*
• Luts, W. (1967).
A. Correlation Coefficient "r".
Sxy
T * \f< • ,2y
Where 1-
1* x end y ntand for individual rallies in the two sets
of results respectively.
2 2
2. S and S are the variances of the two sets of
x y
results respectively.
?. Sxy * variance of x.y
Calculated as follows:-
Sxy «• JL. - (il> <{7>^
Where
n ■ number of pairs of x.y values*
The equation of the test fitting straight "regression" line




A = y - hxf y and x being the means of the
two sets of results.
11.
■
Formula for calculating whole blood folate as mug/ml. of
>. ■■■■■■ .hum ■ i.i» ■■■■ **i..mt* ■■■"«■
packed red eella.
* Erythrocyte folate whole blood folate - serum folate




* (Mollen and Hoffbrand 1965).
*
®P>4














Megaloblastic folate deficient cases*
MCHC MCV Plasma RBC SO F/A Xylose
folate folate B12 absorb, gm/5 hr.
raug/ml. mug/ml. uug/ml.











ViL- ; ■tv - A".
6 23 F 10*9
7 4l F 11*5
Lg * , . ,,
''














\ - . '.uitt?:.
10 84 F 7*9
11 64 M 6*7
12 85 F 6.0
13 32 F 4.5
14 50 F 9.2
15 35 F 3.9
16 87 M 6.0
17 60 M 8.5
18 75 F 12.5
19 85 F 5.11
20 60 M 6.4
21 70 M 9.4
22 50 F 9.0






m>- ! 'V' .JkiSrJ*
IV-: '
































































































































































poor Diet def* .
good Hodgkins Dis.
poor 1 Diet def.





































4.9 - 101 4 Early megalo. PA
18 163 M 3.9 - - - Frankly ft ? PA
8.2 108 tl 4.5 13.0 mm - it tl PA
8.5 247 n 4.0 - - - 11 II ? PA
8.1 171 •1 6.6 12.0 mm - it It PA
12.0 204 0 2.0 10.0 - - ti tl PA
11
217 49 tt 5.0 19.0 mm - H tt PA
13.0 148 N 1.8 - 210 14 Early megalo. PA
11.0 213 ti 3.0 12.0 - - Frankly tt PA
3.4 47 ti 2.2 10.9 - - H tt PA
2.9 98 it 3.6 12.1 - - It tt PA
3.1 151 1.0 34.0 - - It it PA
4.3 88 W ?-,i 2.0
_ V mm ft tt ? PA
8.0 130
'
« 4*0 - - ft tt 1 PA
10.0 188 tt 4.5 - 23 2 Early megalo. pa
3.2 61 • W 5.0 - - - Frankly tt ? PA
4.4 105 f» 3.0 - - - H ■ <*• ■ 11 ? PA
6.3 148 II ' 3.1 - - - ft tt ? PA
M i 167 II 2.8 - - - tl ti ? PA
CO•ITS 104 t# 2.2 15.7 - H ti PA
2.4 50 II 1.3 - 1.8 26 tt •• PA
10.0 181 m 4.0 14 - tt H PA
5.0 124 ft 2.9 - - -
tt tt ? PA
11.0 130 ft 0.59 - 273 6
tt tt PA
7.3 157 t» 1.6 - 33 0.0
tt M PA
8.0 215 It 3.3 ""
tt tt ? PA
* . The lower normal limit of the
factor output is 300 ng units.
post, histamine intrinsic
x The total body uptake
is less than 30%.
of Co5-B
^2 in pernicious anaemia .** !






































Data on iron deficient patients<
Hb.- PCV SBC
* I ' .
x 10
......











•f1! ' *'r .<
M 8.8 33 5.49 27
p
P 6.8 23 3.86 29
n





11 15 M 10.91
12 35 F .r.
13 69 F 5,1|
14 59 M 5-9J
15 50 K 7*1!
16 45 M 6,9I




































= Chronic lymphocytic leukaemia,
= Duodenal ulcer,
s Faecal occult blood.
S.I. *= Serum iron.
T.I.B.C.= Total iron binding capacity.
Aetiol ofy.
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5.6 25 61 3.0 4.5 346 30 400 ft C.L.L. *
3 40 r 8.J v 29 5.01 28 58 1.5 4.5 335 10 480 tl ? - FOB •
4
« fl«PW
16 F 5.9 jp 25 3.99lppi'0
24
' 1
63 3.6 3.6 409 20 400 ft D.C, *









30 67 <1.0 4.2 350 15 450 tt Malabsorption*
6 56 ? 7.5 29<>.09 26 71 3.0 5.4 44? 15 450 If Ca. Caeovi*.
7 79 H 5.8| 20 3.11
7*0? v .;. sV*!*K !
29 64 1.5 7-2 412 10 285 H Dietary
7 -▼* FOB.
224 27 535 M Malabsorption*
565 15 500 H ? -ve FOB
177 30 450 « "4 Dietary
7 -/f FOB
3.0 196 20 390 t» ? -ve JOB
"
TMP.JMfeiWW-. -
... V"""— vS* ~ FOB"3-S
•; %£<&**&'■ -
' fyw'ijLv.;. -.;: _
- S#
ftoo
.1 ... No blood loss
6.1 375 10 375
ri No blood stool*.
3.2 447 15 480
■ /•
M Haemorrhoids.
2.7 195 25 390
19 D.U.
2.4 197 20 360 11 D.U.


















Blood Film Bone Marrow
1 53 M + +
2 64 F + +
# 62 F + +
A 78 F + +
5 42 F ++
6 65 F ++
7 73 F ♦++
8 71 M ++
9 42 H ++
10 57 M +
n 51 F + +
12 64 M ♦++
13 70 M + +
14 42 M ++
15 74 F ♦+
G 3b£- 52 T +*•><•+
17 64 f ++ +
18 69 F + + +
19 35 M ++ +
20 35 M ++ +
21 51 F 4 +
22 40 F +4
23 57 F + + +
24 33 ? 44 +
25 63 M 4
26 49 H 4 +
27 23 H 44
28 62 M 4
29 16 F 44
30 46 F 4+
31 73 F 4+
32 26 F +
33 63 M 44
34 62 F 44 +
35 54 M 4+
36 59 M 44






































RBC S'e fflff/8 hrs. Sensitised Diet F/A
folate B12 FIGLU tfroc.A sheep cell + ,- absor
mug/ml uug/rnl titre + ,-
12.4 41 70 Normal Early mcgaloe 1.3 120 168 55 185 1/512+ + Nor*
12.7 - 32 II Normoblastic 1.4 183 560 25 13 1/128+ ♦ tt
11.5 37 48 n tt 1.5 103 256 12 12 1/1024+ + tt
8.7 - 52 tt ti 4.4 209 308 16 212 1/16- + It
9.6, i 31 50 « ft 0.7 121 488 70 62 1/32- ♦ H
10.5 34 30 ff tt 2.0 88 424 9 11 1A024+ ♦ mm
7.3 28 107 «i tt 3.6 194 220 99 9 1/16- ♦ -
9.8 36 58 Hypochromic n 2.4 290 448 69 39 1/256+ ♦
13.2 - 70 Normal it 3.7 282 672 42 91 1/1024+ ♦ -
12.8 38 20 it « 3.0 199 568 13 4 1/32- + -
9.4 34 70 H ti 2.3 225 566 14 25 1/32- + -
12.4 39 43 ft ft 6.1 251 472 14 25 1/256+ ♦ -
14.6 45 22 « Early megalo* 2.3 189 288 44 22 1A28+ + -
12.8 - 28 It Normoblastic 1.9 109 448 28 41 1A024+ ♦ -
8.4 31 53 ft tt 2.9 175 500 32 0 1/256* ♦ -
U2.0 «■ 81 f! ESf-iJ- magaxci x.x acr? ?oo - a i/ie= - g
8.2 26 112 11 « 1.4 153 472 60 0 1/128+ +
-
10.6 33 112 rt ti 2.0 136 240 67 6l4 1/512+ +
-
9.4 34 72 it ♦« 2.5 163 148 138 15 1/32-
+ -
9.4 32 75 tt Normoblastic 1.9 172 320 33 13 1/256+
♦ mm
9.7 34 30 it
t* 3.0 208 392 335 281 1/32+ ♦ -
8.6 32 48 19
« 2.7 259 251 46 0 1/1024+ + -
9.0 — 77 «
ft 3.9 135 552 60 100 1/16- ♦ -
10.2 74 A w 4.3 304 386 273 -0 1/512+
♦ -
12.8 40 22 H Early megalo# 2.8 208 244 58
26 1/256+ + -
14.0 ;'VlP- 32 » Normoblastic 1.6 113 473
0 4 1/512+ + mm
11.8 34 91 « 4.6 175 443
0 21 1A28+ ♦ -
12.1 38 22 ft
99 2.2 205 168 0 0 1/1024+ ♦ Nora.
9.4 31 52 tt
ft 1.3 91 1000 - «• 1/64- +
»t
8.6 29 62 ft
If 2.3 113 168 35 75 1/512+ +
»
8.4 26 90 Hypochromic ft 1.7 111 392 37 55 1A6-
+ tt
13.3 _ 39 Normal
W 2.2 192 220 23 5 1/64- ♦ »
9.4 26 36 Occ .fflacroQr. Early raegalo. 1.5 55
212 28 17 1A6- - tt
7.8 26 135 Hypochromic Normoblastic 2.9 232 291 35 3 1/256+
♦ tt
11.8 m, ' mm Normal
ft 1.8 99 272 21 9 1/256+ »t
12.2 - 67
If 1.6 99 496 49 140 1/256+ + A
8.4 in 70 Hvitochroaic ft 1.8 215 132 15 18 1A28+ ♦
tt
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